

1 **Fine-mapping of melanoma-associated genomic regions identifies novel causal SNPs in**
2 **the *MTAP/CDKN2A* and *CASP8* loci**

3
4 Carolina Castaneda-Garcia¹, Vivek Iyer², Jérémie Nsengimana³, Adam Trower⁴, Alastair Droop²,
5 Kevin M. Brown⁵, Jiyeon Choi⁵, Tongwu Zhang⁵, Mark Harland⁴, Julia A. Newton-Bishop⁴, D.
6 Timothy Bishop⁴, David J. Adams^{2,6}, Mark. M. Iles^{4,6}, Carla Daniela Robles-Espinoza^{1,2,6}

7
8 ¹Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional
9 Autónoma de México, Santiago de Querétaro, México, 76230

10 ²Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB101SA, UK

11 ³Biostatistics Research Group, Population Health Sciences Institute, Faculty of Medical
12 Sciences, Newcastle University, Newcastle upon Tyne, NE2 4BN, UK

13 ⁴Leeds Institute of Medical Research and Leeds Institute for Data Analytics, University of Leeds,
14 LS9 7TF, Leeds, UK

15 ⁵Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of
16 Health, Bethesda, MD 20892, USA

17 ⁶To whom correspondence should be addressed: da1@sanger.ac.uk (D.J.A.),
18 m.m.iles@leeds.ac.uk (M.M.I.), drobles@liigh.unam.mx (C.D.R.-E.)

19
20
21 **Abstract**

22 A number of genomic regions have been associated with melanoma risk through genome-wide
23 association studies, however, the causal variants underlying the majority of these associations
24 remain unknown. Here, we sequenced either the full locus or the functional regions including
25 exons of 19 melanoma-associated loci in 1,977 British melanoma cases and 754 controls.
26 Variant filtering followed by Fisher's exact test analyses identified 88 variants associated with
27 melanoma risk. Sequential conditional logistic regressions identified the distinct haplotypes on
28 which variants lie, and massively parallel reporter assays (MPRA) provided biological insights
29 into how these variants influence gene function. We performed further analyses to link variants
30 to melanoma risk phenotypes and assess their association with melanoma-specific survival. Our
31 analyses replicate previously known associations in the *MC1R* and *TYR* loci, while identifying
32 novel potentially causal variants at the *MTAP/CDKN2A* and *CASP8* loci. These results increase
33 our understanding of the architecture of melanoma risk and outcome.

34 Introduction

35 Cutaneous malignant melanoma (melanoma) is the most aggressive type of skin cancer and
36 originates from melanocytes, the pigment-producing cells of the skin. Ultraviolet radiation
37 exposure is thought to be the main etiological risk factor for melanoma; notably, the number of
38 diagnoses of melanoma have dramatically increased in the last decades¹. Genetic contributions
39 to this type of cancer have also been identified, mainly through linkage and sequencing studies
40 in the context of high-penetrance disease in melanoma-prone families² and by genome-wide
41 association studies (GWASs) in population ascertained cases³⁻⁵.

42
43 High-penetrance genetic variants in genes such as cyclin-dependent kinase inhibitor 2A
44 (*CDKN2A*)⁶, cyclin-dependent kinase 4 (*CDK4*)⁷, telomerase reverse transcriptase (*TERT*)⁸,
45 protection of telomeres 1 (*POT1*)^{9,10}, and other telomere-associated genes are found in
46 approximately half of melanoma-prone families¹¹, and are known to mediate risk for developing
47 the disease. Common variants that increase the risk of developing melanoma have also been
48 investigated, with the most recent melanoma GWAS meta-analysis including 36,760 cases and
49 375,188 controls. The authors found 54 genome-wide significant regions⁴. However, as these
50 studies are based on genotyping data, the actual genetic alterations within these regions that
51 increase risk are unknown. The identification of the causal germline genetic lesions that increase
52 cancer predisposition is clinically important, as they may be used as biomarkers for diagnosis,
53 risk stratification, and targeted treatment¹².

54
55 In this study, we identified genetic variants within melanoma-associated haplotypes by sequence
56 analysis of melanoma-associated regions in a British case-control cohort. Our analyses point to
57 a number of potentially causal variants within the *MTAP/CDKN2A* and *CASP8* loci, in addition to
58 confirming already known variants in the *MC1R* and *TYR* loci. These results refine our knowledge
59 of the genetic architecture of melanoma and contribute to the identification of potential
60 mechanisms of disease development.

61
62 **Results**

63 We sequenced two full melanoma predisposition loci (methylthioadenosine phosphorylase
64 [*MTAP/CDKN2A* and *TERT*) (**Methods**) as well as the promoters, exons and DNase I
65 hypersensitivity sites associated to genes falling in 17 other melanoma-associated regions in
66 1,977 melanoma cases and 754 matched controls from the UK population as part of the Leeds
67 Melanoma case-control study (**Table 1, Methods**). After variant calling and filtering, we retained
68 25,653 genetic variants across all regions of interest, from which, only 11,615 were previously
69 tested in the latest meta-analysis⁴. We conducted individual Fisher's exact tests (**Methods**) of
70 association to melanoma for each of the retained variants and defined 88 single nucleotide
71 polymorphisms (SNPs) as the most informative SNPs regarding risk haplotypes at $P < 0.001$
72 within seven genomic regions (**Figure 1, Supplementary Table 1**). In this study, we define a
73 haplotype as the group of all variants within a region whose association to the phenotype
74 depends on the most associated variant in that group (referred to as the lead SNP).

75

76 For all associated variants in each region, we performed stepwise conditional logistic regressions
77 to detect the distinct haplotypes where these variants are located. In order to identify potential
78 biological mechanisms through which these variants may act, we also conducted association
79 trend tests with a number of melanoma-linked phenotypes in the UKBioBank and ENGAGE
80 cohorts (**Methods**). For candidate variants in the *MTAP/CDKN2A* and *CASP8* regions, we also
81 integrated previously-published data from a massively parallel reporter assay (MPRA) designed
82 to identify risk-associated variants with allelic *cis*-regulatory activity (Choi et al., 2020). Finally,
83 we also evaluated melanoma-specific survival (MSS) in carriers and non-carriers of melanoma-
84 associated lead variants in the Leeds Melanoma cohort (**Methods**). In the following sections, we
85 discuss the *MC1R* and *TYR* regions as proof of concept and *MTAP/CDKN2A* and *CASP8* where
86 we identified novel potential candidate variants. Results for the other regions where associated
87 variants were found can be found in the **Supplementary Note**.

88

89 *Proof of concept: Fine-mapping of the melanocortin 1 receptor (MC1R) and tyrosinase (TYR) loci*
90 *identifies established risk variants*

91 The locus most highly associated with melanoma in our dataset was *MC1R* (**Figure 1**), which
92 reflects previous reports⁵. As part of our experiment, we targeted all exons and the promoter of
93 *MC1R*. Subsequent association tests revealed 8 variants as significantly associated with
94 melanoma (Fisher's exact tests $P < 0.001$, **Figure 2a**, **Supplementary Table 1**). Stepwise
95 conditional logistic regressions were then deployed to identify two independent haplotypes in
96 this region, with the lead SNPs for these two independent signals corresponding to the known
97 *MC1R* melanoma-predisposing alleles p.Arg151Cys (rs1805007) and p.Arg160Trp (rs1805008),
98 while the next significant SNP (association $P < 0.002$) after adjusting for the previous two
99 corresponded to a third haplotype with lead SNP p.Asp294His (rs1805009), which has also been
100 strongly associated to melanoma development (**Figure 2a**). The allelic frequencies (AFs) and
101 odds ratios (ORs) calculated from this dataset closely reflect what has been reported in the
102 literature (**Figure 2a**, **Supplementary Table 1**).

103

104 Next, we assessed the association of these SNPs with known melanoma-linked phenotypes
105 using the UKBioBank and ENGAGE datasets, in order to search for clues of the biological
106 mechanisms through which they may be acting to increase melanoma risk. The minor alleles of
107 the three leading SNPs in *MC1R* haplotypes (rs1805007, rs1805008 and rs1805009), as well as
108 the other 8 associated SNPs, are all associated with hair color: red hair against all others, number
109 of incidents of childhood sunburn, skin pigmentation, and tanning ability at genome-wide
110 significance (**Figure 2b**, **Supplementary Table 2**). These are all established associations given
111 the biological role that *MC1R* plays in melanin production and the role of melanin in promoting
112 the tanning response to protect DNA from damage¹³. The lead SNP rs1805007 was also
113 associated with naevus count, which was also observed to a lesser degree with the other SNPs
114 in its haplotype. Finally, the least common of these haplotypes, the minor allele of rs1805009
115 (p.Asp294His), showed a positive association with MSS (**Figure 2c**), consistent with our previous
116 observations¹⁴.

117

118 For the tyrosinase locus (*TYR*), we sequenced the promoter, all exons and nearby DNase I
119 hypersensitivity sites (DHSs) from the *TYR* and *NOX4* genes (**Methods**). Overall, the association
120 test found 16 variants associated with melanoma, all of them in the same haplotype led by
121 rs1126809 (**Figure 3a, Supplementary Table 1**). This variant codes for p.Arg402Gln, a known
122 melanoma predisposition allele¹⁵. After the first logistic regression, the next most significant
123 variant was rs490934 (association $P < 0.03$), which falls in an intron in *NOX4*. As expected, all
124 assessable variants in the first haplotype are associated with childhood sunburn occasions, ease
125 of skin tanning and skin pigmentation, whereas rs490934 was associated with the same
126 phenotypes with the exception of childhood sunburn occasions (**Figure 3b**). No significant
127 associations with patient survival were found. The lead SNPs we identified in *MC1R* and *TYR* are
128 the same ones identified by Landi *et al* in their latest meta-analysis⁴. These results indicate that
129 we are able to identify melanoma-associated germline alleles, patient phenotypes related to
130 outcomes of biological mechanisms through which such alleles may act, and their potential
131 associations with patient survival.

132
133 *Methylthioadenosine Phosphorylase (MTAP) / Cyclin-dependent kinase inhibitor 2A (CDKN2A)*
134 *region*. The *MTAP/CDKN2A* locus encompasses two functional tumour suppressor genes,
135 *CDKN2A* and *CDKN2B*, that are known to play a role in familial and sporadic melanoma risk, as
136 well as a number of other genes with potential involvement in this disease. For this region, we
137 targeted the full genomic space between GRCh38 chr9:21665209-22151817, which included
138 *MTAP*, *CDKN2A*, *CDKN2B* and *CDKN2B-AS1/ANRIL* as genes of interest (**Table 1, Methods**).
139 Overall, our association tests identified 44 SNPs associated with melanoma (**Supplementary**
140 **Table 1, Figure 4a**). These all fell into one haplotype, with lead SNP rs10811623, an intronic
141 variant in the *MTAP* gene that falls within a large promoter-flanking regulatory region. The next
142 most significant SNP after the first logistic regression was rs2518722, which falls into a separate
143 haplotype (association P -value < 0.0035) and within long non-coding RNA *AL359922.1*, encoded
144 in the reverse strand and which overlaps *MTAP*. All the SNPs in both haplotypes that could be
145 evaluated for their association to melanoma-linked phenotypes showed an association with
146 naevus count (**Supplementary Table 2, Figure 4b**). MRPA performed on 13 of these SNPs
147 show regulatory potential for rs10811617 (with a significant departure from the background and
148 allelic difference) and, to a lesser extent, to rs80138396 (with a significant allelic difference).
149 These SNPs are in moderate ($r^2 = 0.53, 0.58$ respectively) linkage disequilibrium (LD) with our
150 lead SNP (rs10811623) and high LD ($r^2 = 0.93, 1$ respectively) with rs871024, which is the one
151 identified as the lead by Landi *et al*⁴ (**Supplementary Table 3**). In our analysis, rs871024 is also
152 found associated with melanoma (P -value 2.8×10^{-4}) with a similar OR (1.25, compared to 1.18
153 in Landi *et al.*, 2020⁴). According to the LD-pop tool (Alexander & Machiela, 2020), the LD in the
154 British population between these two alleles (r^2) is 0.59 in the 1000 Genomes Project, making
155 them moderately correlated. This indicates that both rs10811623, as the most significantly
156 associated SNP in this study, and rs10811617 could potentially encode functional alleles in this
157 region. The lead SNP for the second haplotype, rs2518722, has not been previously identified
158 as associated with melanoma, and was not significant by our criteria after the original Fisher's

159 exact test. Of note, carriers of the alternative allele at rs2518722 were found to have better MSS
160 than non-carriers (**Figure 4c**).

161
162 An important issue in melanoma genetics is the classification of novel variants in known risk
163 genes. Sixteen *CDKN2A* coding variants were identified in this study (**Supplementary Table 4**),
164 including one novel, heterozygous variant in a case (p.Trp160Arg), predicted deleterious by the
165 SIFT and PolyPhen-2 algorithms^{16,17}, a rare frameshift variant in a case (rs779306249,
166 p.Glu33GlyfsTer30) and an inframe variant in a case (rs779983400, p.Glu113del). The only
167 coding variant moderately associated with melanoma was rs3731249 (p.Ala148Thr, OR: 1.395,
168 *P*-value = 0.0821), which has been described as a risk variant previously in other populations^{3,18}.

169
170 *Caspase 8 (CASP8) region*. For this region, we targeted the promoter, exons and associated
171 DHSs of all genes of interest overlapping GRCh38 chr2:201047085-201724509, which includes
172 *CASP8*, *ALS2CR12* (Also known as *FLACC1*), *CFLAR*, and *TRAK2*. Overall, our association tests
173 identified 14 SNPs associated with melanoma (**Figure 5a, Supplementary Table 1, Methods**)
174 in one haplotype with lead SNP rs3769818, and after the first logistic regression, the next most
175 significant variant was SNP rs191947901 (association *P*-value <0.004). No associations were
176 found for any of these SNPs with melanoma-linked phenotypes (**Figure 5b**); however, carriers of
177 the alternative allele at the lead SNP of the first haplotype (rs3769818-G), were found to have
178 worse MSS than non-carriers (**Figure 5c**). Landi et al.⁴ identified rs10931936 as the lead SNP in
179 this region, which was not captured in our data as our experiment preceded their publication.
180 However, according to LD-pop, these are in complete LD in the British population in the 1000
181 Genomes Project ($r^2 = 1$). A missense variant in *CASP8*, rs3769823 coding for p.Lys14Arg and
182 which lies in a vitamin D binding site¹⁹, was also found in this haplotype. This variant, though
183 moderately correlated with the lead SNP ($r^2=0.6917$), has been found to explain the signal for
184 basal cell carcinoma risk at this locus¹⁸. MRPs also showed that the reference allele (A) is
185 functional and associated with *cis*-regulatory activity as an activator (**Supplementary Table 4**).
186 Therefore, rs3769823 is a plausible candidate for being the causal SNP in this region, both
187 because it alters the protein sequence of caspase 8 and because appears to be *cis*-regulatory.

188
189 *Other regions*. Variants significantly associated with melanoma were also found in three other
190 regions: oculocutaneous albinism 2 (*OCA2*, chr15:27670078-28337214), E-cadherin (*CDH1*,
191 chr16:68528729-68923897) and cyclin D1 (*CCND1*, chr11:69210414-69803433)
192 (**Supplementary Figures 1, 2 and 3**). Three, one and one significantly associated variants were
193 found, respectively (**Supplementary note**).

194
195
196
197 **Discussion**
198 Predicting an individual's risk of disease provides an opportunity to preempt surveillance, to
199 counsel patients about behaviors that may mitigate their likelihood of developing a condition,
200 and also provides fundamental insights into disease biology. In this study, we perform the largest

201 melanoma resequencing project to our knowledge, exploring the allelic landscape of melanoma
202 loci by analyzing over 2,700 individuals. Our analysis identifies established melanoma risk
203 variants such as disruptive coding alleles of *MC1R* and *TYR*. Importantly, we were also able to
204 extend our analysis of germline alleles in melanoma patients to identify candidate functional
205 variants at loci including *MTAP/CDKN2A* and *CASP8*, where risk alleles were associated with
206 phenotypes such as naevus count and survival.

207
208 In performing the studies outlined in our paper, we aimed to illuminate biological insights into
209 how melanoma risk loci contribute to disease development. One notable observation we made
210 was that the lead variant at the *CASP8* locus (rs3769818) was associated both with melanoma
211 (G allele) and with patient outcome (specifically the A allele with better survival) but not with
212 melanoma-linked phenotypes, such as tanning or naevus count. By analysis of MPRA data, the
213 linked variant rs3769823, also identified in this study, was found to be associated with altered
214 *cis*-regulatory activity and to fall into a canonical vitamin D binding site. More specifically, the
215 rs3769823-A allele, which is linked to rs3769818-A, appears to be associated with *cis*-regulatory
216 activity as an activator. The observation that a variant that activates *CASP8* may also be
217 associated with better outcome is fitting given the role of *CASP8* in pro-apoptotic pathways.
218 Therefore, this variant may appear to activate the expression of *CASP8*, a gene which plays a
219 key role in programmed cell death mediating processes such as apoptosis, necroptosis and
220 pyroptosis²⁰. However, it is the alternative allele (G) the one that shows an association with higher
221 *CASP8* levels in both a previously published eQTL analysis in primary melanocyte cultures²¹ and
222 a range of tissues in the GTex database, as well as lower *ALS2CR12* levels in thyroid tissue²².
223 *CASP8* has also been found to be overexpressed in a range of cancers including prostate and
224 renal cancer where it is associated with a poor outcome. A potential explanation for this
225 observation could be the role of *CASP8* in increasing NF- κ B levels, an event we²³ and others^{24,25}
226 have previously linked to enhanced melanoma cell growth. Thus, individuals who carry
227 rs3769823-G may be predisposed to melanoma development via a role for this variant in
228 influencing a switch from pro-apoptotic to anti-apoptotic functions of NF- κ B which may
229 associate this variant with patient outcome as opposed to other phenotypes. The potential role
230 for vitamin D signalling in this context requires further exploration with an extensive literature
231 linking low vitamin D levels to both risk of melanoma development and poor melanoma-
232 associated outcomes²⁶.

233
234 Another intriguing observation we made, explored to some degree previously¹⁴, was the
235 dichotomous relationship between risk alleles and outcome. For example, alleles at the *CDKN2A*
236 and *MC1R* loci strongly associate with disease risk but are inversely associated with patient
237 outcome. In the case of *MC1R*, tumours from patients with *R* alleles carry more somatic
238 mutations²⁷ leading to the hypothesis that they are more immunogenic or have neo-antigens that
239 are more easily recognized by the immune system. Mechanistically, it is less clear why individuals
240 with common genetic variants at the *CDKN2A* locus that are associated to melanoma, such as
241 rs2518722-T which we highlight in our study, would have a better outcome. It is intriguing to
242 note that carriers of high-penetrance *CDKN2A* melanoma susceptibility variants also appear to
243 have a better outcome when compared to individuals who develop melanoma sporadically. Of

244 course, these variants act in conjunction with many others present in carriers to modulate
245 disease onset, tumour evolution and therapy response, so further studies are warranted.

246
247 Thus, in this study we provide a detailed exploration of melanoma risk loci and biological insights
248 into the processes that drive this malignancy. These data provide a foundation for further
249 functional studies such as CRISPR genome-editing of risk loci or other *in vivo* or *in vitro*-based
250 experiments that, in the near future, should deepen our knowledge of the influence of genetic
251 variants on melanoma development.

252
253 **Methods**

254 *Ascertainment of cases and controls.* Ethical approval for the Leeds Melanoma Cohort Study
255 was granted by the North East - York Research Ethics Committee (MREC 1/3/57), the Patient
256 Information Advisory Group (PIAG 3-09(d)/2003) and further approved by the Sanger Institute
257 Human Materials and Data Management Committee. Patients have been part of previous GWAS
258 melanoma projects³⁻⁵. The inclusion criteria for patients have been previously published²⁸. Briefly,
259 population-ascertained incident melanoma cases in a geographically defined area of Yorkshire
260 and the northern region of the UK were recruited to a case-control study to form the Leeds Case
261 Control cohort; and from these, germline DNA was obtained from 1,977 cases and 488 controls
262 along with extensive patient clinical data. Two hundred and sixty-six samples from control
263 subjects were also obtained through the Wellcome Trust Case Control Consortium²⁹ (WTCCC)
264 for a total number of 754 controls. All individuals part of this study were previously confirmed to
265 be of European origin through a combination of self-reporting and PCA of genome-wide
266 genotype data.

267
268 *Selection of candidate regions.* Nineteen regions previously reported as associated regions, from
269 which 15 were genome-wide significant loci from a melanoma GWAS meta-analysis (Law et al.,
270 2015) and four that were identified as candidate melanoma susceptibility regions by a preliminary
271 version of the same GWAS, were selected for inclusion in a custom design sequencing panel
272 (**Table 1**). All genes falling within the limits of linkage disequilibrium around the melanoma
273 GWAS-associated region were included in the panel. Exons, promoters, and DNase I
274 hypersensitivity sites associated with these genes were included as follows:

- 275
- 276 - Exons. For each gene of interest in each associated region, all exons belonging to it,
277 regardless of the transcript biotype (e.g., protein-coding or others) as annotated in
278 Ensembl³⁰ release 69 were included. 100 bp of intron on either side of each exon was
279 included to ensure the appropriate capture of potential splice site alterations.
 - 280
 - 281 - Promoters. For each gene, the transcription start site (TSS) as annotated in Ensembl
282 release 69 was noted. Additional TSSs per gene were manually curated to include other
283 possible alternative TSSs associated with non-canonical transcripts in the gene. From all
284 these, 5,000bp upstream to the TSS were included in the design (**Supplementary Table**
285 **5**).

286
287 - DNAse I hypersensitivity sites (DHS). For each gene, a window of 100kb of sequence
288 around the gene was searched for DHSs annotated in melanoma cells profiled by
289 ENCODE³¹. The cell lines that were considered in this search were Colo829, Mel2183,
290 Melano, and RPMI7951. No thresholding was applied to this selection, and the union of
291 all annotated regions in all cell lines was included (**Supplementary Table 6**).

292
293 - Full loci. Two full loci containing the limits of linkage disequilibrium around the GWAS
294 signal were included in this design. The *MTAP/CDKN2A* region was defined from
295 GRCh38 chr9:21665209-22151817, and the *TERT* region was defined from
296 chr5:1142197-1447788.

297
298 In total, the target genomic space amounted to 2.061 Mb. Target region coordinates were
299 submitted through the SureDesign platform to Agilent Technologies for their manufacture with a
300 tiling density of 2x, ‘moderately stringent’ masking, and ‘maximize performance’ boosting.
301 Information associated with this design is included in **Supplementary Table 7**.

302 *Targeted DNA sequencing*. DNA was extracted from blood from consenting participants and
303 processed as previously reported in Newton-Bishop et al., 2010³². Sequencing was done in two
304 batches using the Illumina Genome Analyzer platform. Reads were aligned to the GRCh38
305 reference genome using the BWA-MEM algorithm³³, achieving comparable coverage in cases
306 and controls in all regions. Duplicate marking was done using biobambam streaming
307 markduplicates³⁴.

308 *Variant calling and quality control*. For each aligned file, the GATK v4.1.0.0 HaplotypeCaller was
309 run to create a genomic variant call format (gVCF) file. For joint calling, the individual target
310 regions were combined into 103 batches. Each batch (20 target regions) was supplied to the
311 GATK GenomicsDBImport tool along with all the gvcf called in the previous step. The resulting
312 genomicsDB was then supplied to the GATK GenotypeGVCFs tool, creating a single vcf file with
313 genotypes for all samples for all target regions in the batch. These steps were performed for all
314 103 batches. The vcf files for all batches were combined together using bcftools concat v1.9³⁵
315 to create a final single vcf file containing 40,936 variants. Samples were separated into
316 sequencing batches and phenotype cohort (cases and controls). The following filters were
317 applied for variants in each batch, and each cohort (4 groups in total):

318
319 - A *P*-value from a Hardy-Weinberg Equilibrium test³⁶ was calculated for each variant site
320 using PLINK v1.90b3v (www.cog-genomics.org/plink/1.9/)³⁷ only in both control batches.
321 All variants with *P* < 0.001 were excluded.
322
323 - Average GQ values were calculated³⁸. All variants with an average GQ < 30 were filtered
324 out. Sites with more than 0.05 missing genotypes on the basis of their proportion were
325 also filtered out.

326

327 Batches were joined keeping only variants that were common among them after these filters.
328 Then further filters were applied:

- 329
- 330 - All variants overlapping low-complexity regions (LCRs)³⁹ were filtered out.
 - 331
 - 332 - For each site, the rate of genotype missingness was calculated and a Fisher's exact test³⁷
333 was performed between cases and controls; any site with $P < 0.05$ was excluded.
 - 334
 - 335 - The probability of the called samples exhibiting excess heterozygosity with respect to the
336 null hypothesis that the samples are unrelated was estimated using the GATK v4.1.1.0-
337 ExcessHet⁴⁰. All variants had an ExcessHet value below 54.96, which corresponds to a
338 P -value of 3.4×10^{-06} .
 - 339
 - 340 - The GATK v4.1.1.0 Variant Quality Score Recalibration (VQSR)⁴⁰ was applied following
341 their Best Practices for exome sequencing⁴¹ (DePristo et al., 2011). We retained variants
342 in the 99.4% and 99.7% tranche sensitivity threshold for SNVs and indels respectively.
343 Tranche plots for the SNVs can be seen in **Supplementary Figure 4**.
 - 344
 - 345 - All variants that overlapped alterations found in the gnomAD database version 3.0⁴², but
346 that were annotated as not passed in this database, were filtered out. This filter was
347 included to eliminate potential systematic artifacts that can be detected by gnomAD
348 given its scale.
 - 349
 - 350 - Finally, the allele frequency (AF) of each variant site in controls was compared to that
351 reported for the non-Finnish European population (NFE) in the gnomAD dataset⁴². The
352 difference in AF between both populations was converted into z-scores using the
353 following formula: $z = (X - \mu) / \sigma$, where x is a single data value, μ is the population mean
354 and σ is the population standard deviation. Any site with a z-score ≤ -9 or ≥ 9 was filtered
355 out (**Supplementary Figure 5**).
- 356

357 In the end, a set of 25,653 high-quality variants were selected for further analyses.

358

359 *Variant association analyses.* Individual Fisher's exact tests of association to the phenotype were
360 conducted for each variant site. No adjustments were made for multiple comparisons; as these
361 regions were selected on the basis of a previously known association, a $P < 0.001$ was
362 considered to indicate an informative variant leading the association of an identifiable haplotype.
363 In order to detect clusters of variants of interest, a stepwise logistic regression controlling for the
364 most significantly-associated variant in each region was performed for those regions with more
365 than one variant passing the significance threshold. For this cluster selection, the threshold of a
366 P -value considered an outcome of nonrandom association with the variants selected to
367 condition the logistic regression model was set to 0.1. PLINK v1.90b3v ([www.cog-
368 genomics.org/plink/1.9](http://www.cog-genomics.org/plink/1.9))³⁷ was used for these statistical analyses. The aligned read sequences
369 of all variants passing the threshold of significance were manually inspected using Samtools⁴³

370 view to detect potential mapping errors, resulting in 96 variants that passed these filters (these
371 include the next most significant variant and any additional variants gaining significance at the
372 predetermined threshold after applying logistic regressions). BCFtools⁴³ and VCFtools⁴⁴ were
373 used to facilitate the data handling. In this study, we define a haplotype as all the variants within
374 a region whose association to the phenotype depends on the most associated variant (referred
375 to as the lead SNP).

376
377 *Association of each of the variants identified above with melanoma risk phenotypes in a larger*
378 *cohort.* To investigate their contribution to the known melanoma risk phenotypes, candidate
379 variants were tested for their association with various pigmentation phenotypes: skin
380 pigmentation, childhood sunburn occasions, hair colour: red against all others, hair colour:
381 blond, light brown, dark brown, black, ease of skin tanning and combined pigmentation score
382 (first principal component of a PCA of all of these), using the UK Biobank data as previously
383 described⁴ for hair color, and which involves treating traits with more than two values as being
384 ordinal. In addition, the association of the candidate variants to telomere length was also
385 assessed using GWAS data from a meta-analysis by the ENGAGE consortium⁴⁵. The association
386 of the candidate variants to naevus count was done using the naevus count data included in the
387 latest melanoma meta-analysis paper⁴.

388
389 *Genetic association with melanoma outcomes.* Candidate SNPs tagging the haplotypes
390 significantly associated with melanoma risk were tested for association, in the same case-control
391 cohort, with melanoma-specific survival (MSS), age, sex, tumour thickness, ulceration and
392 mitotic rate. We found no association with any of these variables except for MSS. MSS
393 information was available for 613 patients with a median follow up of 8 years⁴⁶. Univariable Cox
394 proportional hazards regression was applied and Kaplan-Meier survival curves were plotted in
395 STATA v14 (StataCorp LLC, 2019) comparing two groups: carriers vs non-carriers of the risk
396 allele.

397
398 *Functional testing of variants in MTAP/CDKN2A and CASP8 via massively parallel reporter assays*
399 *(MPRA).* Data generated previously as reported by Choi and colleagues⁴⁷ were paired to the
400 candidate risk haplotypes for both regions. The overlapping matches associated or in linkage
401 disequilibrium with the haplotypes here reported were assessed in their allelic transcriptional
402 function with the MPRA approach. In brief, variants that are in LD ($r^2 > 0.4$) with GWAS leads from
403 the melanoma meta-analysis conducted by Law and colleagues⁵ and secondary leads identified
404 through fine-mapping were selected. The potential as an enhancer or promoter element was
405 tested using a 145-bp genomic sequence encompassing each variant site and was investigated
406 in luciferase constructs. Each allele of each variant, designed in both forward and reverse
407 directions, was linked to 10 unique barcode sequences. The surrounding 20bp of each variant
408 were scrambled to be tested as a null. The transcription of barcodes of each element transfected
409 into a melanoma cell line (UACC903, to represent melanoma-specific *trans*-acting factors) as
410 well as the cell line HEK293FT (to represent non-cell-type-specific activity in a highly
411 transfectable cell line) was measured by sequencing. Variants with a significant difference
412 between two alleles comparing the ratio of RNA TPM/DNA TPM (tags per million, e.g. normalized

413 tag count) are reported as those with allelic transcriptional activity (FDR<0.01; two-sided Wald
414 test with robust sandwich type variance estimate; multiple comparisons adjusted using
415 Benjamini & Hochberg method).

416 **Acknowledgments**

417 The wish to acknowledge Ian Dunham, Laurens Wilming, Jennifer H. Barrett, and John Taylor for
418 help with the definition of samples to include and regions to sequence. The authors wish to thank
419 Luis A. Aguilar, Alejandro de León and Carlos S. Flores from the Laboratorio Nacional de
420 Visualización Científica Avanzada, and Jair S. García Sotelo, Abigayl Hernández, Eglee Lomelín,
421 Alejandra Castillo and Carina Díaz from the International Laboratory for Human Genome
422 Research, National Autonomous University of Mexico. This study makes use of data generated
423 by the Wellcome Trust Case Control Consortium. A full list of the investigators who contributed
424 to the generation of the data is available from www.wtccc.org.uk.

425

426 **Funding**

427 This work was supported by Cancer Research UK [to D.J.A.], the Medical Research Council
428 [MR/S01473X/1 to C.D.R.-E. and D.J.A] and Programa de Apoyo a Proyectos de Investigación
429 e Innovación Tecnológica (PAPIIT UNAM) [IA202020 to C.D.R.-E.]. C.D.R.-E. is also supported
430 by CONACyT [A3-S-31603 and A1-S-30165], the Melanoma Research Alliance [825924,
431 <https://doi.org/10.48050/pc.gr.143729>], the Academy of Medical Sciences through a Newton
432 Advanced Fellowship [NAF\R2\180782] and a Wellcome Sanger Institute International
433 Fellowship. C.C.G. is a PhD student from Programa de Doctorado en Ciencias Biomédicas,
434 Universidad Nacional Autónoma de México (UNAM), and is supported by CONACyT [holder no.
435 330123, scholarship no. 385365]. This work represents a substantial part of her dissertation.
436 Funding for the project was provided by the Wellcome Trust under award 076113.

437

438 **Data and code availability**

439 Sequence data for all cases and controls in this study have been deposited at the European
440 Genome-phenome Archive and can be found under accession number EGAC00001000205. All
441 code used in this study can be found in https://github.com/citosina/melanoma_reseq. MPRA
442 data are available in the NCBI Gene Expression Omnibus as a SuperSeries under the accession
443 number GSE129250.

- 444 1. Parkin, D. M., Mesher, D. & Sasieni, P. 13. Cancers attributable to solar (ultraviolet) radiation
445 exposure in the UK in 2010. *Br. J. Cancer* **105**, S66–S69 (2011).
- 446 2. Harland, M. *et al.* Prevalence and predictors of germline CDKN2A mutations for melanoma
447 cases from Australia, Spain and the United Kingdom. *Hered. Cancer Clin. Pract.* **12**, (2014).
- 448 3. Barrett, J. H. *et al.* Genome-wide association study identifies three new melanoma
449 susceptibility loci. *Nat. Genet.* **43**, 1108–1113 (2011).
- 450 4. Landi, M. T. *et al.* Genome-wide association meta-analyses combining multiple risk
451 phenotypes provide insights into the genetic architecture of cutaneous melanoma
452 susceptibility. *Nat. Genet.* **52**, 494–504 (2020).
- 453 5. Law, M. H. *et al.* Genome-wide meta-analysis identifies five new susceptibility loci for
454 cutaneous malignant melanoma. *Nat. Genet.* **47**, 987–995 (2015).
- 455 6. Cannon-Albright, L. *et al.* Assignment of a locus for familial melanoma, MLM, to chromosome
456 9p13-p22. *Science* **258**, 1148 (1992).
- 457 7. Zuo, L. *et al.* Germline mutations in the p16INK4a binding domain of CDK4 in familial
458 melanoma. *Nat. Genet.* **12**, 97–99 (1996).
- 459 8. Horn, S. *et al.* TERT promoter mutations in familial and sporadic melanoma. *Science* **339**,
460 959–961 (2013).
- 461 9. Robles-Espinoza, C. D. *et al.* POT1 loss-of-function variants predispose to familial
462 melanoma. *Nat. Genet.* **46**, 478–481 (2014).
- 463 10. Shi, J. *et al.* Rare missense variants in POT1 predispose to familial cutaneous malignant
464 melanoma. *Nat. Genet.* **46**, 482–486 (2014).
- 465 11. Aoude, L. G., Wadt, K. A. W., Pritchard, A. L. & Hayward, N. K. Genetics of familial melanoma:
466 20 years after *CDKN2A*. *Pigment Cell Melanoma Res.* **28**, 148–160 (2015).
- 467 12. Fletcher, O. & Houlston, R. S. Architecture of inherited susceptibility to common cancer. *Nat.*
468 *Rev. Cancer* **10**, 353–361 (2010).
- 469 13. Brenner, M. & Hearing, V. J. The Protective Role of Melanin Against UV Damage in Human
470 Skin. *Photochem. Photobiol.* **84**, 539–549 (2008).
- 471 14. Davies, J. R. *et al.* Inherited variants in the MC1R gene and survival from cutaneous
472 melanoma: a BioGenoMEL study. *Pigment Cell Melanoma Res.* **25**, 384–394 (2012).
- 473 15. Duffy, D. L. *et al.* Multiple Pigmentation Gene Polymorphisms Account for a Substantial
474 Proportion of Risk of Cutaneous Malignant Melanoma. *J. Invest. Dermatol.* **130**, 520–528
475 (2010).
- 476 16. Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting functional effect of human missense
477 mutations using PolyPhen-2. *Curr. Protoc. Hum. Genet.* **Chapter 7**, Unit7.20 (2013).
- 478 17. Ng, P. C. & Henikoff, S. SIFT: Predicting amino acid changes that affect protein function.
479 *Nucleic Acids Res.* **31**, 3812–3814 (2003).
- 480 18. Lin, Y. *et al.* Association between genetic variation within vitamin D receptor-DNA binding
481 sites and risk of basal cell carcinoma. *Int. J. Cancer* **140**, 2085–2091 (2017).
- 482 19. Ramagopalan, S. V. *et al.* A ChIP-seq defined genome-wide map of vitamin D receptor
483 binding: Associations with disease and evolution. *Genome Res.* **20**, 1352–1360 (2010).
- 484 20. Liu, S. *et al.* Discovery of CASP8 as a potential biomarker for high-risk prostate cancer
485 through a high-multiplex immunoassay. *Sci. Rep.* **11**, 7612 (2021).

- 486 21. Zhang, T. *et al.* Cell-type-specific eQTL of primary melanocytes facilitates identification of
487 melanoma susceptibility genes. *Genome Res.* **28**, 1621–1635 (2018).
- 488 22. Carithers, L. J. *et al.* A Novel Approach to High-Quality Postmortem Tissue Procurement:
489 The GTEx Project. *Biopreservation Biobanking* **13**, 311–319 (2015).
- 490 23. Del Castillo Velasco-Herrera, M. *et al.* Comparative genomics reveals that loss of lunatic
491 fringe (LFNG) promotes melanoma metastasis. *Mol. Oncol.* **12**, 239–255 (2018).
- 492 24. Stansel, T., Wickline, S. A. & Pan, H. NF- κ B Inhibition Suppresses Experimental Melanoma
493 Lung Metastasis. *J. Cancer Sci. Clin. Ther.* **4**, 256–265 (2020).
- 494 25. Ueda, Y. & Richmond, A. NF- κ B activation in melanoma. *Pigment Cell Res. Spons. Eur. Soc.*
495 *Pigment Cell Res. Int. Pigment Cell Soc.* **19**, 112–124 (2006).
- 496 26. O’Shea, S. J., Davies, J. R. & Newton-Bishop, J. A. Vitamin D, vitamin A, the primary
497 melanoma transcriptome and survival. *Br. J. Dermatol.* **175 Suppl 2**, 30–34 (2016).
- 498 27. Robles-Espinoza, C. D. *et al.* Germline MC1R status influences somatic mutation burden in
499 melanoma. *Nat. Commun.* **7**, 12064 (2016).
- 500 28. Randerson-Moor, J. A. *et al.* Vitamin D receptor gene polymorphisms, serum 25-
501 hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis
502 of published VDR data. *Eur. J. Cancer* **45**, 3271–3281 (2009).
- 503 29. Burton, P. R. *et al.* Genome-wide association study of 14,000 cases of seven common
504 diseases and 3,000 shared controls. *Nature* **447**, 661–678 (2007).
- 505 30. Yates, A. D. *et al.* Ensembl 2020. *Nucleic Acids Res.* **48**, D682–D688 (2020).
- 506 31. Davis, C. A. *et al.* The Encyclopedia of DNA elements (ENCODE): data portal update. *Nucleic*
507 *Acids Res.* **46**, D794–D801 (2018).
- 508 32. Newton-Bishop, J. A. *et al.* Melanocytic Nevi, Nevus Genes, and Melanoma Risk in a Large
509 Case-Control Study in the United Kingdom. *Cancer Epidemiol. Prev. Biomark.* **19**, 2043–
510 2054 (2010).
- 511 33. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform.
512 *Bioinforma. Oxf. Engl.* **25**, 1754–1760 (2009).
- 513 34. Tischler, G. & Leonard, S. biobambam: tools for read pair collation based algorithms on BAM
514 files. *Source Code Biol. Med.* **9**, 13 (2014).
- 515 35. Li, H. A statistical framework for SNP calling, mutation discovery, association mapping and
516 population genetical parameter estimation from sequencing data. *Bioinformatics* **27**, 2987–
517 2993 (2011).
- 518 36. Wigginton, J. E., Cutler, D. J. & Abecasis, G. R. A Note on Exact Tests of Hardy-Weinberg
519 Equilibrium. *Am. J. Hum. Genet.* **76**, 887–893 (2005).
- 520 37. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer
521 datasets. *GigaScience* **4**, 7 (2015).
- 522 38. Carson, A. R. *et al.* Effective filtering strategies to improve data quality from population-
523 based whole exome sequencing studies. *BMC Bioinformatics* **15**, 125 (2014).
- 524 39. Li, H. Towards Better Understanding of Artifacts in Variant Calling from High-Coverage
525 Samples. *Bioinformatics* **30**, 2843–2851 (2014).
- 526 40. McKenna, A. *et al.* The Genome Analysis Toolkit: A MapReduce framework for analyzing
527 next-generation DNA sequencing data. *Genome Res.* **20**, 1297–1303 (2010).

- 528 41. DePristo, M. A. *et al.* A framework for variation discovery and genotyping using next-
529 generation DNA sequencing data. *Nat. Genet.* **43**, 491–498 (2011).
- 530 42. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in
531 141,456 humans. *Nature* **581**, 434–443 (2020).
- 532 43. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *GigaScience* **10**, (2021).
- 533 44. Danecek, P. *et al.* The variant call format and VCFtools. *Bioinformatics* **27**, 2156–2158 (2011).
- 534 45. Li, C. *et al.* Genome-wide Association Analysis in Humans Links Nucleotide Metabolism to
535 Leukocyte Telomere Length. *Am. J. Hum. Genet.* **106**, 389–404 (2020).
- 536 46. Thakur, R. *et al.* Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage
537 I Melanoma. *Clin. Cancer Res.* **25**, 7424–7435 (2019).
- 538 47. Choi, J. *et al.* Massively parallel reporter assays of melanoma risk variants identify MX2 as a
539 gene promoting melanoma. *Nat. Commun.* **11**, 2718 (2020).
- 540 48. Boyle, A. P. *et al.* Annotation of functional variation in personal genomes using RegulomeDB.
541 *Genome Res.* **22**, 1790–1797 (2012).
- 542 49. The International HapMap Consortium. The International HapMap Project. *Nature* **426**, 789–
543 796 (2003).
- 544 50. Machiela, M. J. & Chanock, S. J. LDassoc: an online tool for interactively exploring genome-
545 wide association study results and prioritizing variants for functional investigation.
546 *Bioinforma. Oxf. Engl.* **34**, 887–889 (2018).
- 547
- 548
- 549

550 **Figure Legends**

551

552 **Figure 1. Genomic regions with variants associated with melanoma.** Seven genomic
553 association graphs, one per locus, are shown. The X axis shows the genomic location and the Y
554 axis displays the degree of association ($\log_{10}(P\text{-value})$). The horizontal gray line depicts the
555 significance threshold ($P = 0.001$). Circle colours represent the allelic frequency of the alternate
556 allele.

557

558 **Figure 2. Association of variants in the *MC1R* region with melanoma, melanoma-linked
559 phenotypes and survival. a)** The top panel depicts the $-\log_{10}(P\text{ value})$ of association with
560 melanoma of variants significantly associated ($P\text{ value} < 1 \times 10^{-7}$) from the most recent melanoma
561 meta-analysis⁴. Numbers inside the circles display the RegulomeDB⁴⁸ rank, the circle size
562 represents the minor allele frequency. The variant in purple is the most associated in the meta-
563 analysis (rs1805007), the red shade depicts the linkage disequilibrium (r^2) value with respect to
564 it. The horizontal blue line indicates $P = 5 \times 10^{-8}$. The overlay Y axis depicts the combined
565 recombination rate from HapMap⁴⁹. The middle panel depicts the genes in the genomic region.
566 These panels were interactively plotted by LD-assoc (<https://ldlink.nci.nih.gov/>)⁵⁰. The lower
567 panel shows the results of the association tests and the logistic regressions in the melanoma
568 case-control cohort in this study. The colour of the circle represents the linkage disequilibrium
569 (r^2) value with respect to the most associated variant, and the circle size represents the allelic
570 frequency of the minor allele. **b)** P-value of association tests of all melanoma-associated variants
571 with distinct melanoma-linked phenotypes. r1, r2 and r3 represent distinct haplotypes, P-values
572 were truncated at $\log_{10}(-\log_{10} > 2.488)$. **c)** Survival fraction of patients in this melanoma case-
573 control cohort grouped by carrier status of rs1805009.

574

575 **Figure 3. Association of variants in the *TYR* region with melanoma and melanoma-linked
576 phenotypes. a)** The top panel depicts, in the Y axis, the $-\log_{10}(P\text{ value})$ of association with
577 melanoma of variants significantly associated ($P\text{ value} < 1 \times 10^{-7}$) from the most recent melanoma
578 meta-analysis⁴ as well as the combined recombination rate from HapMap⁴⁹. Numbers inside the
579 circles hold regulatory information (if any) from RegulomeDB⁴⁸, the circle size represents the
580 minor allele frequency. The variant in purple is the most associated in the meta-analysis
581 (rs1126809), the red shade depicts the linkage disequilibrium (r^2) value with respect to it. The
582 horizontal blue line indicates $P = 5 \times 10^{-8}$. The genes in the genomic region are depicted in the
583 middle panel. These panels were interactively plotted by LDassoc (<https://ldlink.nci.nih.gov/>)⁵⁰.
584 The results of the association tests and logistic regressions in the melanoma case-control cohort
585 in this study are shown in the lower panel. The colour of the circle represents the linkage
586 disequilibrium (r^2) value with respect to the most associated variant, and the circle size represents
587 the allelic frequency of the minor allele. **b)** P-value of association tests of all melanoma-
588 associated variants with distinct melanoma-linked phenotypes. r1 and r2 represent distinct
589 haplotypes, P-values were truncated at $\log_{10}(-\log_{10} > 2.488)$.

590

591 **Figure 4. Association of variants in the *MTAP/CDKN2A* region with melanoma melanoma-**
592 **linked phenotypes and survival. a)** The top panel shows the combined recombination rate from
593 HapMap and the $-\log_{10}(P\text{-value})$ of association with melanoma of variants significantly associated
594 (P value 1×10^{-7}) from the most recent melanoma meta-analysis⁴ as well as the combined
595 recombination rate from HapMap⁴⁹. Numbers inside the circles hold regulatory information (if
596 any) from RegulomeDB⁴⁸, the circle size represents the minor allele frequency. The purple dot is
597 the most associated in the meta-analysis (rs871024), the red shade depicts the linkage
598 disequilibrium (r^2) value with respect to it. The horizontal blue line indicates $P=5 \times 10^{-8}$. The genes
599 in the genomic region are depicted in the middle panel. These panels were interactively plotted
600 by LDassoc (<https://ldlink.nci.nih.gov/>)⁵⁰. The results of the association tests and logistic
601 regressions in the melanoma cohort in this study are shown in the lower panel. The colour of the
602 circle represents the linkage disequilibrium (r^2) value with respect to the most associated variant,
603 and the circle size represents the allelic frequency of the minor allele. **b)** P -value of association
604 tests of all melanoma-associated variants with distinct melanoma-linked phenotypes. r1 and r2
605 represent distinct haplotypes. **c)** Survival fraction of patients in the melanoma cohort in this study
606 grouped by carrier status of rs2518722.

607
608 **Figure 5. Association of variants in the *CASP8* region with melanoma melanoma-linked**
609 **phenotypes and survival. a)** The top panel shows the combined recombination rate from
610 HapMap and the $-\log_{10}(P\text{ value})$ of association with melanoma of variants significantly associated
611 (P value 1×10^{-7}) from the most recent melanoma meta-analysis⁴ as well as the combined
612 recombination rate from HapMap⁴⁹. Numbers inside the circles hold regulatory information (if
613 any) from RegulomeDB⁴⁸, the circle size represents the minor allele frequency. The purple dot
614 corresponds to rs3769823, the red shade depicts the linkage disequilibrium (r^2) value with
615 respect to it. The horizontal blue line indicates $P=5 \times 10^{-8}$. The genes in the genomic region are
616 depicted in the middle panel. These panels were interactively plotted by LDassoc
617 (<https://ldlink.nci.nih.gov/>)⁵⁰. The results of the association tests and logistic regressions in the
618 melanoma cohort in this study are shown in the lower panel. The colour of the circle represents
619 the linkage disequilibrium (r^2) value with respect to the most associated variant, and the circle
620 size represents the allelic frequency of the minor allele. **b)** P -value of association tests of all
621 melanoma-associated variants with distinct melanoma-linked phenotypes. r1 and r2 represent
622 distinct haplotypes. **c)** Survival fraction of patients in the melanoma cohort in this study grouped
623 by carrier status of rs3769818.

624
625

626 **Table legends**

627

628 **Table 1. Loci included in this study.** The location (GRCh38), genes of interest and the targeted
629 regions associated to each locus are indicated.

630

631

632 **Supplementary Figure Legends**

633

634 **Supplementary Figure 1. Association of variants in the *OCA2* region with melanoma**
635 **melanoma-linked phenotypes. a)** Regional association P -values for identified melanoma
636 susceptibility variants significantly associated (P -value 1×10^{-7}) from the most recent melanoma
637 meta-analysis⁴ is depicted in the top panel as well as the combined recombination rate from
638 HapMap in the shared Y axis. The numbers contained in the circles represent RegulomeDB⁴⁸
639 (Boyle et al., 2012) regulatory classification, and the circle size reflects minor allele frequency.
640 The purple circle corresponds to rs129123832, the top SNP in the region reported in the latest
641 meta-analysis (Landi et al., 2020). The red shade depicts the linkage disequilibrium (r^2) value with
642 respect to it. The horizontal blue line indicates $P=5 \times 10^{-8}$. The genes in the genomic region are
643 depicted in the middle panel. These panels were interactively plotted by LDassoc
644 (<https://ldlink.nci.nih.gov/>)⁵⁰. The results of the association tests and logistic regressions in the
645 melanoma cohort in this study are shown in the lower panel. The colour of the circle represents
646 the linkage disequilibrium (r^2) value with respect to the most associated variant, and the circle
647 size represents the allelic frequency of the minor allele. **b)** P -value of association tests of all
648 melanoma-associated variants with distinct melanoma-linked phenotypes. r_1 and r_2 represent
649 distinct haplotypes, P -values were truncated at $\log_{10}(-\log_{10} > 2.488)$.

650

651 **Supplementary Figure 2. Association of variants in the *CDH1* region with melanoma**
652 **melanoma-linked phenotypes and survival. a)** Regional association P -values for identified
653 melanoma susceptibility variants significantly associated (P -value 1×10^{-7}) from the most recent
654 melanoma meta-analysis⁴ is depicted in the top panel as well as the combined recombination
655 rate from HapMap in the shared Y axis. The numbers contained in the circles represent
656 RegulomeDB⁴⁸ regulatory classification, and the circle size reflects minor allele frequency. The
657 purple circle corresponds to rs4420522, the top SNP in the region reported in the latest meta-
658 analysis. The red shade depicts the linkage disequilibrium (r^2) value with respect to it. The
659 horizontal blue line indicates $P=5 \times 10^{-8}$. The genes in the genomic region are depicted in the
660 middle panel. These panels were interactively plotted by LDassoc (<https://ldlink.nci.nih.gov/>)⁵⁰.
661 The results of the association tests and logistic regressions in the melanoma cohort in this study
662 are shown in the lower panel. The colour of the circle represents the linkage disequilibrium (r^2)
663 value with respect to the most associated variant, and the circle size represents the allelic
664 frequency of the minor allele. **b)** P -value of association tests of all melanoma-associated variants
665 with distinct melanoma-linked phenotypes. r_1 and r_2 represent distinct haplotypes. **c)** Survival
666 fraction of patients in the Leeds Melanoma cohort grouped by carrier status of rs35789195.

667

668 **Supplementary Figure 3. Association of variants in the *CCND1* region with melanoma**
669 **melanoma-linked phenotypes. a)** Regional association P -values for identified melanoma
670 susceptibility variants significantly associated (P -value 1×10^{-7}) from the most recent melanoma
671 meta-analysis⁴ is depicted in the top panel as well as the combined recombination rate from
672 HapMap in the shared Y axis. The numbers contained in the circles represent RegulomeDB⁴⁸
673 regulatory classification, and the circle size reflects minor allele frequency. The purple circle

674 corresponds to rs4354713, the red shade depicts the linkage disequilibrium (r^2) value with
675 respect to it. The horizontal blue line indicates $P=5\times 10^{-8}$. The genes in the genomic region are
676 depicted in the middle panel. These panels were interactively plotted by LDassoc
677 (<https://ldlink.nci.nih.gov/>)⁵⁰. The results of the association tests and logistic regressions in the
678 melanoma cohort in this study are shown in the lower panel. The colour of the circle represents
679 the linkage disequilibrium (r^2) value with respect to the most associated variant, and the circle
680 size represents the allelic frequency of the minor allele. **b)** P -value of association tests of all
681 melanoma-associated variants with distinct melanoma-linked phenotypes. r1 and r2 represent
682 distinct haplotypes.

683
684 **Supplementary Figure 4. Tranche plots for Variant Quality Score Recalibration (VQSR).** The
685 threshold selected for this study was 99.4.

686
687 **Supplementary Figure 5. Comparison of allelic frequencies of variants identified in this**
688 **study and variants annotated in GnomAD.** Variants that passed this filter are depicted. The
689 allelic frequency in this study is depicted in the X axis whereas that one in GnomAD can be found
690 in the Y axis.

691
692

693 **Supplementary Table Legends**

694

695 **Supplementary Table 1. List of variants significantly associated with melanoma in this**
696 **study.** The column 'INFO' includes information about the variant consequences, including gene
697 symbol and Ensembl transcript ID (Ensembl release 99)³⁰. The 'P-value' column has the Fisher's
698 test association value, 'P value 1st' and 'P value 2nd' refer to the P-values after the first and
699 second logistic regressions respectively, controlling for the most associated variant. AF: Allele
700 frequency, OR: Odds ratio. The 'rx' nomenclature in the 'Region' column refers to variants in the
701 same haplotype ('r1' is the highest associated haplotype, 'r2' the second highest, etc).

702

703 **Supplementary Table 2. Association between associated SNPs and melanoma-linked**
704 **traits.** 'REF' refers to the reference allele, 'ALT' is the alternative allele. OR: Odds ratio, SE:
705 Standard error, P_P-value, BETA: Beta coefficient from linear regression. Sunburn: sunburn
706 occasions during childhood, Skin: skin pigmentation, tanning: Ease of tanning, pigscore:
707 pigmentation score from PCA, TEL: Telomere length, NAEV: naevus count.

708

709 **Supplementary Table 3. MPRA results for selected variants in the *MTAP/CDKN2A* and**
710 ***CASP8* regions.** 'Function' refers to the inferred function of a SNP, activator means that the
711 alternative allele is significantly associated to higher mRNA expression of the target gene.
712 'UACC903/HEK293' refers to analyses considering both cells together, 'UACC903 Only' refers
713 to these cells considered alone. FDR: False discovery rate.

714

715 **Supplementary Table 4. Coding variants in *CDKN2A* found in this study.** Different lines per
716 variant are shown if more than one transcript is affected by the variant.

717

718 **Supplementary Table 5. Transcription start sites annotated for each gene of interest.**
719 Coordinates are in GRCh37, as this annotation was done with Ensembl release 69.

720

721 **Supplementary Table 6. Coordinates (GRCh37) of DNase I Hypersensitivity sites captured**
722 **per targeted gene.**

723

724 **Supplementary Table 7. Design parameters for the capture probes used in this study.** This
725 table includes all relevant parameters as reported by Agilent Technologies. The coordinates for
726 all targeted regions can be found after the design, target and probe summary information.

727 **Supplementary note**

728

729 Variants associated with melanoma were also found in these regions:

730

731 *Oculocutaneous Albinism 2 (OCA2) region*. For this region, we sequenced exons and promoters
732 of the genes *OCA2* and *HERC2*, both of which have been previously associated with melanoma
733 development. The initial individual association tests identified three SNPs associated with
734 melanoma (**Supplementary Figure 1a, Supplementary Table 1**), all in one haplotype with lead
735 SNP rs12593929, falling on an intron in *HERC2*. The most significant SNP after the first logistic
736 regression, in a separate haplotype, was chr15:28168711 AAG/A, a small deletion not found in
737 dbSNP, and that had an initial association *P* value < 0.03. The three SNPs in the first haplotype
738 were associated with a range of pigmentation traits (**Supplementary Figure 1b**), as expected,
739 whereas the SNP leading the second haplotype could not be imputed in the UKBioBank data
740 and therefore association scores could not be calculated. However, no association was found
741 between this SNP and the one described as the lead SNP in Landi *et al*⁴ (rs12913832). No SNPs
742 in this region were found associated with MSS.

743

744 *E-cadherin (CDH1) region*. We sequenced the promoters and exons of two genes of interest
745 (*CDH1* and *CDH3*) (**Table 1**). The initial association tests identified an intronic variant within
746 *CDH1*, rs181642569, as associated with melanoma risk (**Supplementary Figure 2a,**
747 **Supplementary Table 1**). The second most associated SNP after logistic regression was
748 rs35789195, but no melanoma-linked phenotypes were found associated with these
749 (**Supplementary Figure 2b**). For rs35789195, carriers of the alternative allele A were found to
750 have a survival advantage over non-carriers (**Supplementary Figure 2c**). However, both SNPs
751 seem unlinked to the lead SNP from the meta-analysis identified by Landi *et al* 2020⁴ (rs4420522).

752

753 *Cyclin D1 (CCND1) region*. We sequenced exons, promoters and DHSs for four genes of interest:
754 *CCND1*, *MYEOV*, *ORAOV1* and *FGF19* (**Table 1**). The initial Fisher's association tests identified
755 a downstream SNP from *FGF19*, rs17136816, as associated with melanoma with *P*-value =
756 0.0006689 and OR of the reference allele of 1.844 (**Supplementary Table 1, Supplementary**
757 **Figure 3a**). However, it is not associated with the lead SNP identified in Landi *et al* in this region
758 (rs4354713). The next most significant SNP was rs77925438, also not correlated with rs4354713.
759 No melanoma-linked traits were found associated with any of these two SNPs (**Supplementary**
760 **Figure 3b**).




Figure 1






Figure 2





Figure 3





Figure 4

P-values and regional LD for rs3769823 in GBR








Figure 5

Table 1. Loci included in this study. The location (GRCh38), genes of interest and the targeted regions associated to each locus are indicated.




Location (GRCh38)	Genes of Interest Encoded in the Region	Targeted regions
chr1:150754900-151073108	<i>ARNT, SETDB1</i>	Exons, promoters and DHSs
chr1:226258651-226499883	<i>PARP1</i>	Exons, promoters and DHSs
chr2:201047085-201724509	<i>CASP8, ALS2CR12, CFLAR, TRAK2</i>	Exons, promoters and DHSs
chr4:24692289-25055958	<i>SOD3, CCDC149</i>	Exons and promoters
chr5:1142197-1447788	<i>TERT, CLPTM1L</i>	Full locus
chr5:33840139-34064027	<i>SLC45A2</i>	Exons, promoters and DHSs
chr6:83948233-84292890	<i>MRAP2, KIAA1009</i>	Exons and promoters
chr9:21665209-22151817	<i>MTAP, CDKN2A, CDKN2B, ANRIL</i>	Full locus
chr11:69210414-69803433	<i>CCND1, MYEOV, ORAOV1, FGF19</i>	Exons, promoters and DHSs
chr11:89097917-89675699	<i>TYR, NOX4</i>	Exons, promoters and DHSs
chr11:108136364-108468324	<i>ATM</i>	Exons, promoters and DHSs
chr15:27670078-28337214	<i>OCA2, HERC2</i>	Exons and promoters
chr16:53363904-54384452	<i>FTO, IRX3, RBL2</i>	Exons, promoters (<i>FTO, IRX3, RBL2</i>) and DHSs (<i>FTO</i> and <i>IRX3</i>)
chr16:68528729-68923897	<i>CDH1, CDH3</i>	Exons and promoters
chr16:89806464-90031424	<i>MC1R</i>	Exons and promoters
chr17:80154433-80508392	<i>RNF213</i>	Exons and promoters
chr20:33709976-34374270	<i>ASIP, RALY, EIF2S2, CHMP4B</i>	Exons, promoters and DHSs
chr21:41194545-41512249	<i>MX2, FAM3B</i>	Exons, promoters and DHSs
chr22:37870877-38328731	<i>PLA2G6, SOX10, PICK1, SLC16A8</i>	Exons, promoters and DHSs

a

P-values and regional LD for rs12913832 in GBR



**b**

Supplementary Figure 1




Supplementary Figure 2

a P-values and regional LD for rs4354713 in GBR




Supplementary Figure 3

Supplementary Figure 4



Supplementary Figure 5



Supplementary Table 1. List of variants significantly associated with melanoma in this study. The column 'INFO' includes information about the variant consequences, including gene symbol and Ensembl transcript ID (Ensembl release 99). The 'P-value' column has the Fisher test association value, 'P value 1st' and 'P value 2nd' refer to the P-values after the first and second logistic regressions respectively, controlling for the most associated variant. AF: Allele frequency, OR: Odds ratio. The 'rx' nomenclature in the 'Region' column refers to variants in the same haplotype ('r1' is the highest associated haplotype, 'r2' the second highest, etc)

MC1R

Position	REF	ALT	INFO [Gene Consequence Feature Transcript AA Position AA Change]	Base change	AF in cases	AF in controls	P value	OR	Consequence	P value 1st	P value 2nd	Region	Existing_variation
chr16:89916599	A	T	FANCA missense_variant Transcript ENST00000389301 6 V/D	T/A	0.1267	0.09615	0.001673	1.364	V6D	0.0001071	0.7504	r2	rs1800282&COSV66881217
chr16:89927742	G	C	SPIRE2 upstream_gene_variant Transcript ENST00000378247	C/G	0.629	0.5749	0.0002744	1.253		0.1083		r1	rs1108064
chr16:89911337	C	T	TCF25 3_prime_UTR_variant Transcript ENST00000263346 ,MC1R up	T/C	0.1173	0.08289	0.0002038	1.471		5.06E-06	0.7227	r2	rs11538871&COSV54528897
chr16:89919709	C	T	TUBB3 upstream_gene_variant Transcript ENST00000315491 ,MC1R T/C	T/C	0.1649	0.09416	7.12E-12	1.899	R151C			r1 lead	rs1800507
chr16:89919736	C	T	TUBB3 upstream_gene_variant Transcript ENST00000315491 ,MC1R T/C	T/C	0.1191	0.08355	0.0001255	1.483	R160W	3.39E-06		r2 lead	rs1805008
chr16:89920138	G	C	TUBB3 upstream_gene_variant Transcript ENST00000315491 ,MC1R C/G	C/G	0.03364	0.01724	0.00111	1.984	D294H	0.0004559	0.0002301	r3 lead	rs1805009
chr16:89924435	C	T	TUBB3 intron_variant Transcript ENST00000315491 ,MC1R downstre	T/C	0.1143	0.08289	0.0006684	1.428		2.04E-05	0.1473	r2	rs74415461
chr16:89942655	T	C	variant in other transcript	C/T	0.1356	0.1028	0.001035	1.369		2.63E-05	0.9895	r2	rs74465604
chr16:89958562	C	G	DEF8 intron_variant Transcript ENST00000268676	G/C	0.1619	0.09615	1.93E-10	1.815		0.2501		r1	rs74800773
chr16:89981987	C	T	variant in other transcript	T/C	0.1472	0.08554	4.56E-10	1.845		0.7916		r1	rs45610233
chr16:89996112	G	C	AFG3L1P upstream_gene_variant Transcript ENST00000454997	C/G	0.1553	0.08886	4.44E-11	1.885		0.3282		r1	rs73283859

TYR

Position	REF	ALT	INFO	Base change	AF in cases	AF in controls	P value	OR	Consequence	P value 1st	P value 2nd	Region	Existing_variation
chr11:89097935	G	A	intergenic variant	A/G	0.3728	0.3236	0.0007349	1.242		0.3562		r1	rs11018471
chr11:89168402	G	A	intergenic variant	A/G	0.4904	0.5438	0.0004448	0.8074		0.8291		r1	rs11018519
chr11:89173224	C	G	TYR upstream_gene_variant Transcript ENST00000263321	G/C	0.3612	0.3044	7.88E-05	1.292		0.2412		r1	rs7949856
chr11:89173994	G	A	TYR upstream_gene_variant Transcript ENST00000263321	A/G	0.5549	0.6074	0.0004916	0.8057		0.69		r1	rs7949891
chr11:89174125	A	C	TYR upstream_gene_variant Transcript ENST00000263321	C/A	0.3467	0.2876	3.70E-05	1.315		0.5449		r1	rs35537664
chr11:89174828	G	A	TYR upstream_gene_variant Transcript ENST00000263321	A/G	0.3609	0.3044	8.97E-05	1.291		0.229		r1	rs7925404
chr11:89177421	G	C	TYR upstream_gene_variant Transcript ENST00000263321	C/G	0.4358	0.3753	5.13E-05	1.285		0.9416		r1	rs5021654
chr11:89177653	C	T	TYR upstream_gene_variant Transcript ENST00000263321	T/C	0.436	0.3753	5.12E-05	1.287		0.9636		r1	rs4547091&CR128149
chr11:89182872	GA	G	TYR intron_variant Transcript ENST00000263321	G/GA	0.4363	0.3747	3.93E-05	1.292		0.9732		r1	rs34295137
chr11:89244196	G	A	TYR intron_variant Transcript ENST00000263321	A/G	0.3488	0.2779	5.84E-07	1.392		0.864		r1	rs10501698
chr11:89281187	T	C	TYR intron_variant Transcript ENST00000263321	C/T	0.4274	0.3534	5.97E-07	1.365		0.6351		r1	rs12273884
chr11:89284793	G	A	TYR missense_variant Transcript ENST00000263321 402 R/Q	A/G	0.3407	0.2599	8.53E-09	1.471	R402Q			r1 lead	rs1126809
chr11:89295801	C	T	TYR downstream_gene_variant Transcript ENST00000263321	T/C	0.5025	0.4337	5.51E-06	1.319		0.4194		r1	rs28521275
chr11:89309715	A	C	intergenic variant	C/A	0.4014	0.3282	6.08E-07	1.372		0.5869		r1	rs11018567
chr11:89324933	T	C	NOX4 3_prime_UTR_variant Transcript ENST00000263317	C/T	0.3569	0.2838	2.92E-07	1.4		0.9522		r1	rs11018578
chr11:89339242	T	A	NOX4 intron_variant Transcript ENST00000263317	A/T	0.4684	0.4164	0.0005917	1.235		0.3852		r1	rs317180
chr11:89490448	C	G	NOX4 intron_variant Transcript ENST00000263317	G/C	0.9456	0.9602	0.02683	0.7206		0.009909		r2 lead	rs490934

MTAP

Position	REF	ALT	INFO	Base change	AF in cases	AF in controls	P value	OR	Consequence	P value 1st	P value 2nd	Region	Existing_variation
chr9:21738438	C	G	intergenic variant	G/C	0.4803	0.5305	0.0009605	0.8177		0.598		r1	rs10811604
chr9:21741198	C	T	intergenic variant	T/C	0.4815	0.5318	0.0009666	0.8176		0.591		r1	rs9644821
chr9:21741986	C	T	intergenic variant	T/C	0.4838	0.5338	0.0009703	0.8185		0.6173		r1	rs1556696
chr9:21741994	A	C	intergenic variant	C/A	0.4838	0.5345	0.0008681	0.8163		0.5687		r1	rs1556697
chr9:21747421	C	T	intergenic variant	T/C	0.4843	0.5345	0.000968	0.818		0.6082		r1	rs1372059
chr9:21772038	G	A	intergenic variant	A/G	0.4831	0.5332	0.0009686	0.8182		0.6218		r1	rs7037577
chr9:21773223	A	G	intergenic variant	G/A	0.4831	0.5332	0.0009686	0.8182		0.6191		r1	rs2184551
chr9:21775062	A	G	intergenic variant	G/A	0.4833	0.5338	0.0008699	0.8169		0.588		r1	rs10757254
chr9:21775958	G	A	intergenic variant	A/G	0.4831	0.5332	0.0009686	0.8182		0.6154		r1	rs7021012
chr9:21776632	G	A	intergenic variant	A/G	0.4825	0.5325	0.0009714	0.8187		0.6221		r1	rs10757255
chr9:21780252	G	A	intergenic variant	G/A	0.4856	0.5365	0.0007812	0.8156		0.5549		r1	rs7846749
chr9:21783923	A	A	intergenic variant	A/G	0.4871	0.5378	0.000868	0.8162		0.5624		r1	rs935053
chr9:21785305	C	G	intergenic variant	G/C	0.4866	0.5378	0.0007779	0.8146		0.5309		r1	rs1345022
chr9:21787403	G	C	intergenic variant	C/G	0.4866	0.5378	0.0007779	0.8146		0.5282		r1	rs7018772
chr9:21788082	T	G	intergenic variant	G/T	0.4871	0.5385	0.0006996	0.814		0.5196		r1	rs7038708
chr9:21788524	A	G	intergenic variant	G/A	0.4861	0.5371	0.0007791	0.8151		0.5313		r1	rs7022856
chr9:21790068	A	G	intergenic variant	G/A	0.4858	0.5378	0.0006246	0.8121		0.4823		r1	rs10811617
chr9:21790143	G	C	intergenic variant	C/G	0.4858	0.5378	0.0006246	0.8121		0.4798		r1	rs10811618
chr9:21790670	C	G	intergenic variant	G/C	0.4856	0.5358	0.0009674	0.8178		0.5849		r1	rs1542075
chr9:21790756	A	T	intergenic variant	T/A	0.4727	0.5252	0.0005556	0.8104		0.5296		r1	rs1542076
chr9:21799599	T	C	MTAP upstream_gene_variant Transcript ENST00000580900	C/T	0.4901	0.5424	0.0005593	0.8109		0.4798		r1	rs7033503
chr9:21801531	A	G	MTAP upstream_gene_variant Transcript ENST00000580900	G/A	0.4176	0.4682	0.0007756	0.8144		0.8179		r1	rs4364717
chr9:21803184	G	C	MTAP intron_variant Transcript ENST00000580900	C/G	0.4767	0.5318	0.0002803	0.802		0.405		r1	rs935055
chr9:21803730	T	TCCTAA	MTAP intron_variant Transcript ENST00000580900	TCCTAA/T	0.4765	0.5318	0.0002793	0.8012		0.3947		r1	rs98654170
chr9:21803881	C	A	MTAP intron_variant Transcript ENST00000580900	A/C	0.4765	0.5318	0.0002793	0.8012		0.3947		r1	rs871024
chr9:21804618	A	G	MTAP intron_variant Transcript ENST00000580900	G/A	0.4765	0.5312	0.0003147	0.8033		0.4331		r1	rs869330
chr9:21804694	A	G	MTAP intron_variant Transcript ENST00000580900	G/A	0.4765	0.5318	0.0002793	0.8012		0.3947		r1	rs869329
chr9:21805209	C	CAG	MTAP intron_variant Transcript ENST00000580900	CAG/C	0.4765	0.5318	0.0002793	0.8012		0.3947		r1	rs80138396
chr9:21811155	A	G	MTAP intron_variant Transcript ENST00000580900	G/A	0.4069	0.4682	4.62E-05	0.7794				r1 lead	rs10811623
chr9:21813242	T	C	MTAP intron_variant Transcript ENST00000580900	C/T	0.4901	0.4304	8.10E-05	1.272		0.242		r1	rs72691561
chr9:21813304	A	C	MTAP intron_variant Transcript ENST00000580900	C/A	0.4906	0.4304	7.13E-05	1.275		0.2158		r1	rs72691562

chr9:21813496	C	T	MTAP intron_variant Transcript ENST00000580900	T/C	0.4886	0.4297	0.0001038	1.268	0.2805	r1	rs72691563
chr9:21813519	C	T	MTAP intron_variant Transcript ENST00000580900	T/C	0.4896	0.431	0.0001047	1.266	0.3023	r1	rs72691564
chr9:21816529	A	G	MTAP intron_variant Transcript ENST00000580900	G/A	0.4646	0.5259	5.58E-05	0.7824	0.3579	r1	rs7023329
chr9:21816574	G	A	MTAP intron_variant Transcript ENST00000580900	A/G	0.5073	0.569	4.86E-05	0.7801	0.186	r1	rs7023680
chr9:21816638	T	C	MTAP intron_variant Transcript ENST00000580900	C/T	0.4077	0.4668	8.80E-05	0.7861	0.188	r1	rs10114559&COSV66477123
chr9:21816759	G	A	MTAP missense_variant Transcript ENST00000580900 56 V/I	A/G	0.3859	0.4363	0.0007562	0.8119	0.2078	r1	rs7023954&COSV66477132
chr9:21817755	A	G	MTAP intron_variant Transcript ENST00000580900	G/A	0.4851	0.5391	0.0003965	0.8053	0.4303	r1	rs7027989
chr9:21826539	G	A	MTAP intron_variant Transcript ENST00000580900	A/G	0.4831	0.5351	0.0006236	0.8117	0.5283	r1	rs6475585
chr9:21828243	T	C	MTAP intron_variant Transcript ENST00000580900	C/T	0.5215	0.5789	0.0001477	0.7927	0.305	r1	rs3927738
chr9:21834211	T	C	MTAP intron_variant Transcript ENST00000580900	C/T	0.4186	0.4728	0.0003136	0.8027	0.4901	r1	rs10965153
chr9:21837145	GT	G	MTAP intron_variant Transcript ENST00000580900	G/GT	0.3773	0.4304	0.0003628	0.8021	0.7505	r1	rs34710113
chr9:21838146	A	G	MTAP intron_variant Transcript ENST00000580900	G/A	0.4021	0.4536	0.0005854	0.8103	0.6951	r1	rs7868783
chr9:21840778	G	A	MTAP intron_variant Transcript ENST00000580900	A/G	0.3998	0.4516	0.0005773	0.8091	0.6685	r1	rs4977733
chr9:21952927	C	T	variant in other transcript	T/C	0.2491	0.2885	0.0003353	0.8183	0.003437	r2 lead	rs2518722

CASP8

Position	REF	ALT	INFO	Base change	AF in cases	AF in controls	P value	OR	Consequence	P value 1st	P value 2nd	Region	Existing_variation
chr2:201258272	A	G	CASP8 missense_variant Transcript ENST00000358485 14 K/R	G/A	0.6869	0.7328	0.0009596	0.8001		0.9973		r1	rs3769823&COSV51848843
chr2:201260274	T	C	CASP8 intron_variant Transcript ENST00000358485	C/T	0.719	0.7639	0.0008154	0.7908		0.4022		r1	rs6754084&COSV51859738
chr2:201261892	A	G	CASP8 intron_variant Transcript ENST00000358485	G/A	0.7188	0.7639	0.0007025	0.7898		0.435		r1	rs1861270&COSV51846764
chr2:201263224	A	C	CASP8 intron_variant Transcript ENST00000358485	C/A	0.719	0.7639	0.0008154	0.7908		0.39		r1	rs6435074
chr2:201265585	A	C	CASP8 intron_variant Transcript ENST00000358485	C/A	0.719	0.7639	0.0008154	0.7908		0.39		r1	rs2349070
chr2:201286440	A	G	CASP8 intron_variant Transcript ENST00000358485 ,FLACC1 downstre	G/A	0.7013	0.7527	0.0001707	0.7716				r1 lead	rs3769818
chr2:201286677	G	A	CASP8 3_prime_UTR_variant Transcript ENST00000358485 ,FLACC1 d	A/G	0.2033	0.1631	0.0007202	1.309		0.4203		r1	rs17860428
chr2:201286716	G	C	CASP8 3_prime_UTR_variant Transcript ENST00000358485 ,FLACC1 d	C/G	0.6037	0.6552	0.0004838	0.8019		0.4867		r1	rs3185378
chr2:201288502	C	A	CASP8 downstream_gene_variant Transcript ENST00000358485 ,FLAC	A/C	0.7013	0.7527	0.0001707	0.7716		1		r1	rs700635
chr2:201349425	C	T	FLACC1 intron_variant Transcript ENST00000405148	T/C	0.5797	0.6286	0.00098	0.8146		0.4059		r1	rs6714736
chr2:201350769	C	G	FLACC1 missense_variant Transcript ENST00000405148 43 V/L	G/C	0.5797	0.6286	0.00098	0.8146		0.4059		r1	rs13014235&COSV53786340
chr2:201356718	T	A	FLACC1 intron_variant Transcript ENST00000405148	A/T	0.5797	0.6286	0.00098	0.8146		0.4032		r1	rs6737085
chr2:201384985	A	T	TRAK2 intron_variant Transcript ENST00000332624	T/A	0.1811	0.1412	0.0004518	1.344		0.1945		r1	rs2714486
chr2:201406624	C	T	TRAK2 intron_variant Transcript ENST00000332624 ,SCYL2P1 downstr	T/C	0.1813	0.1419	0.0005313	1.339		0.2147		r1	rs2540334
chr2:201652788	G	C	MPP4 intron_variant Transcript ENST00000409474	C/G	0.00253	0.008621	0.003832	0.2917		0.005472		r2 lead	rs191947901

OCA2

Position	REF	ALT	INFO	Base change	AF in cases	AF in controls	P value	OR	Consequence	P value 1st	P value 2nd	Region	Existing_variation
chr15:28107607	G	A	HERC2 downstream_gene_variant Transcript ENST00000261609	A/G	0.03869	0.06034	0.0007325	0.6268		0.9111		r1	rs79494067
chr15:28114112	G	A	HERC2 intron_variant Transcript ENST00000261609	A/G	0.958	0.9337	0.0003166	1.621				r1 lead	rs12593929
chr15:28132626	C	T	HERC2 intron_variant Transcript ENST00000261609	T/C	0.9575	0.9337	0.000436	1.601		0.9692		r1	rs8025035&COSV55334004
chr15:28168711	AAG	A	HERC2 intron_variant Transcript ENST00000261609	A/AAG	0.0002529	0.002653	0.02258	0.09512		0.03155		r2 lead	-

CDH1

Position	REF	ALT	INFO	Base change	AF in cases	AF in controls	P value	OR	Consequence	P value 1st	P value 2nd	Region	Existing_variation
chr16:68696612	G	A	CDH1 intron_variant Transcript ENST00000264012	A/G	0.02479	0.0378	0.01352	0.647		0.007683		r2 lead	rs35789195
chr16:68770202	T	C	CDH1 intron_variant Transcript ENST00000261769	C/T	0.001265	0.007294	0.0007144	0.1723				r1 lead	rs181642569

CCND1

Position	REF	ALT	INFO	Base change	AF in cases	AF in controls	P value	OR	Consequence	P value 1st	P value 2nd	Region	Existing_variation
chr11:69366942	T	C	variant in other transcript	C/T	0.1449	0.1166	0.006827	1.284		0.01142		r2 lead	rs77925438
chr11:69697346	T	C	FGF19 downstream_gene_variant Transcript ENST00000294312	C/T	0.02049	0.03714	0.0006689	0.5423				r1 lead	rs17136816

Supplementary Table 2. Association between associated SNPs and melanoma-linked traits. *REF* refers to reference allele, *ALT* is alternative allele. OR: Odds ratio, SE: Standard error, P: P-value, BETA: Beta coefficient, Sunburn: sunburn history, Skin: skin colour, tanning: Tanning ability, pigscore: pigmentation score, TEL: Telomere length, NAEV: naevus count.

POS	CHR	ID	SNP2	sunburn_REF	sunburn_ALT	sunburn_sunburn	sunburn_sunburn	sunburn_sunburn	redhair_REF	redhair_ALT	redhair_sunburn	skin_BETA	skin_SE	skin_P	nonredhair_REF	nonredhair_ALT	nonredhair_sunburn	tanning_REF	tanning_ALT	tanning_sunburn	pigscore_REF	pigscore_ALT	pigscore_sunburn	TEL_REF	BETA_NAEV	SE_NAEV	P_NAEV		
21738437	9	rs10811604	9:21738437 G	C	0.995162	0.00674955	0.472469	1.00163	0.0111244	0.883253	0.00319496	0.00314922	0.0178845	-0.00144228	-0.00179046	0.420511	-0.0075196	0.00232256	0.002120532	0.00528785	0.0035443	0.135718	0.001451	0.005001	0.717762	NA	0.005895	9.04E-45	
21741107	9	rs9644821	9:21741107 T	C	0.995008	0.00750046	0.458513	1.00201	0.0111238	0.875048	0.0034027	0.00314992	0.0166899	-0.00172646	-0.00179194	0.475885	-0.0071594	0.00232325	0.00125141	0.00544991	0.00354402	0.124104	0.001481	0.005003	0.807177	1.67E-44	0.00586639	1.67E-44	
21751985	9	rs1565444	9:21751985 T	C	0.995151	0.00674441	0.498985	1.00364	0.0111559	0.975907	0.0032085	0.00314941	0.0173039	-0.0033927	-0.00337890	0.434129	-0.0073564	0.00232374	0.00112987	0.00535831	0.00354414	0.117851	0.001464	0.005001	0.768298	1.14E-44	0.00586205	1.14E-44	
21741993	9	rs1556697	9:21741993 C	A	0.995425	0.00674472	0.496629	1.00045	0.0111616	0.968075	0.00321052	0.00314823	0.0172595	-0.00139234	-0.00178912	0.436435	-0.007579	0.00232088	0.00109248	0.00554755	0.00354415	0.117262	0.00148	0.005	0.762011	NA	0.00586202	1.14E-44	
21747420	9	rs1372059	9:21747420 T	C	0.995442	0.00673438	0.498105	1.00042	0.0111115	0.970119	0.0032141	0.00314803	0.0171123	-0.0013905	-0.00178886	0.436974	-0.0075582	0.00232054	0.0011257	0.0055291	0.00354412	0.118431	0.001578	0.004993	0.751958	2.47E-44	0.00586377	2.47E-44	
21772037	9	rs10075518	9:21772037 A	G	0.995147	0.00675518	0.471426	1.00059	0.0111315	0.957966	0.00324661	0.00315017	0.0111523	-0.00143674	-0.00179166	0.422608	-0.0074344	0.00232416	0.00118035	0.00534215	0.00354666	0.132004	0.001311	0.004997	0.705051	1.05E-45	0.00587026	1.05E-45	
21773222	9	rs2184551	9:21773222 G	A	0.99537	0.00675873	0.492309	1.00045	0.0111382	0.964875	0.00324142	0.00315092	0.0164218	-0.0012849	-0.00179266	0.473256	-0.0071979	0.00232547	0.0019666	0.00536826	0.00354861	0.130336	0.00097	0.005001	0.846214	NA	0.00587027	1.34E-45	
21757061	9	rs10075724	9:21757061 G	A	0.995131	0.00675804	0.470148	1.00774	0.0111367	0.948763	0.00323206	0.00315075	0.0139685	-0.00127837	-0.00179249	0.457734	-0.0071736	0.00232517	0.00203446	0.00537837	0.00354822	0.129272	0.000897	0.004997	0.850929	NA	0.00587091	4.07E-46	
21757957	9	rs10075724	9:21757957 A	G	0.995096	0.00675833	0.466943	1.00039	0.0111371	0.936541	0.003230742	0.00315081	0.0143464	-0.00128485	-0.00179256	0.473517	-0.0072049	0.00232527	0.00194155	0.00536656	0.00354836	0.130431	0.000907	0.004997	0.855936	2.54E-46	0.00587137	2.54E-46	
21776631	9	rs10075725	9:21776631 A	G	0.995139	0.00675876	0.470943	1.00223	0.0111358	0.925977	0.00323252	0.00315089	0.0144675	-0.0012701	-0.00179267	0.459113	-0.0071761	0.00232524	0.0021121	0.00533892	0.00354856	0.13259	0.000965	0.004997	0.846086	2.55E-46	0.00587153	2.55E-46	
21780251	9	rs10784679	9:21780251 G	A	0.995425	0.00674483	0.375435	1.00066	0.0111337	0.983233	0.00324038	0.00315084	0.0111031	-0.00133895	-0.00179262	0.461121	-0.0073161	0.00232539	0.00165393	0.00526885	0.00354807	0.140711	0.00138	0.005	0.769298	NA	0.0058735	1.43E-47	
21783932	9	rs195053	9:21783932 A	G	0.995462	0.00676005	0.419856	1.00141	0.0111394	0.899182	0.0034177	0.00315111	0.0141241	-0.00142478	-0.00179298	0.426821	-0.0072552	0.00232574	0.00118168	0.00535584	0.00354876	0.131245	0.001343	0.005003	0.788317	4.28E-47	0.00586964	4.28E-47	
21785304	9	rs1345022	9:21785304 T	C	0.994465	0.00676021	0.411585	1.00135	0.0111396	0.936077	0.0034214	0.00315113	0.0110795	-0.00143474	-0.00179301	0.426034	-0.0072385	0.00232578	0.00181662	0.00534573	0.00354881	0.13198	0.001496	0.004999	0.764534	NA	0.00587451	5.09E-47	
21787402	9	rs10781772	9:21787402 G	C	0.994941	0.0067607	0.439845	1.00112	0.0111406	0.917879	0.0034015	0.00315122	0.0120741	-0.00145214	-0.00179311	0.418031	-0.0072956	0.00232594	0.00170914	0.00536861	0.0035491	0.130365	0.001199	0.005004	0.810654	8.33E-47	0.00587455	8.33E-47	
21788081	9	rs10780878	9:21788081 G	T	0.994315	0.00676133	0.431245	1.00105	0.0111412	0.926843	0.00340315	0.00315133	0.011836	-0.00147504	-0.00179327	0.4101771	-0.0072839	0.00232608	0.00173988	0.00537385	0.00354929	0.129929	0.001294	0.005006	0.816054	NA	0.00587489	4.03E-47	
21788523	9	rs10076284	9:21788523 G	A	0.994155	0.00676243	0.385912	1.00142	0.0111411	0.88957	0.00333557	0.00315131	0.0130756	-0.00138805	-0.00179321	0.438897	-0.007182	0.00232609	0.00201801	0.00530356	0.00354938	0.135119	0.001236	0.005007	0.830204	NA	0.00587249	7.55E-47	
21790067	9	rs10811617	9:21790067 G	A	0.9938	0.00676215	0.357747	1.0013	0.0111422	0.907133	0.00337043	0.00315142	0.0144709	-0.00138567	-0.00179337	0.439724	-0.0071373	0.00232628	0.00215413	0.00526364	0.00354968	0.140929	0.001182	0.005019	0.818032	NA	0.00587594	2.33E-46	
21790142	9	rs10811618	9:21790142 C	G	0.993304	0.00676219	0.320462	1.00223	0.0111424	0.894304	0.0033904	0.00315146	0.0142461	-0.00138826	-0.00179344	0.43888	-0.0071373	0.00232634	0.00215525	0.0052934	0.00354978	0.142693	0.001186	0.005011	8.22139	5.34E-47	0.0058759	5.34E-47	
21790669	9	rs1542075	9:21790669 G	A	0.993871	0.00676227	0.363731	1.00223	0.0111423	0.841619	0.0033323	0.00315151	0.0136305	-0.00134337	-0.00179344	0.456588	-0.0070044	0.00232639	0.00214629	0.00507723	0.00354983	0.153004	0.001205	0.005011	0.809577	NA	0.00587759	1.19E-46	
21790755	9	rs1542076	9:21790755 T	C	0.993872	0.00676227	0.227106	1.00296	0.0111433	0.790907	0.00350677	0.00315039	0.00940871	-0.000926152	-0.00179208	0.605294	-0.006969	0.00232421	0.00271384	0.00547947	0.00354967	0.122388	0.001374	0.005012	0.808514	NA	0.00587514	8.53E-46	
21799598	9	rs1073503	9:21799598 C	G	0.992398	0.00677074	0.259697	1.00342	0.0111528	0.759762	0.00297488	0.00315303	0.0279013	-0.00118667	-0.00179532	0.507911	-0.0062772	0.00232851	0.00270211	0.00448032	0.00355288	0.207296	3.80E-05	0.005024	0.993945	NA	0.0059395	2.67E-47	
21801530	9	rs4364717	9:21801530 G	T	0.984642	0.0067732	0.0223084	1.00096	0.0111617	0.931659	0.00410857	0.0031504	0.02241032	-0.00010543	-0.00179159	0.959386	-0.0056914	0.00232851	0.0146107	0.00681431	0.0035579	0.0554661	-0.0008014	0.005006	0.870792	NA	0.00589566	1.14E-33	
21803183	9	rs193505	9:21803183 A	G	0.993264	0.00675682	0.317163	1.00167	0.0111317	0.880782	0.00350387	0.00315017	0.00936447	-0.000886567	-0.00179196	0.62078	-0.0068746	0.00232391	0.00309474	0.0055345	0.00354632	0.118611	0.002158	0.005026	0.667711	2.63E-49	0.00587372	2.63E-49	
21803880	9	rs871024	9:21803880 C	C	0.993774	0.00675617	0.355244	1.00157	0.0111305	0.882214	0.0035389	0.00315	0.0135754	-0.00087325	-0.00179195	0.625995	-0.0068771	0.00232362	0.00380105	0.00559827	0.00354592	0.114385	0.001574	0.005008	0.753292	1.17E-49	0.00587229	1.17E-49	
21804617	9	rs108930	9:21804617 G	A	0.993742	0.00675472	0.352875	1.00161	0.0111326	0.885402	0.00352465	0.00315027	0.00869942	-0.000824576	-0.0017921	0.645342	-0.0068841	0.0023241	0.00294451	0.00565611	0.00354663	0.110761	0.001582	0.005008	0.752035	NA	0.00587454	5.93E-50	
21804693	9	rs10811623	9:21804693 G	A	0.99361	0.00675725	0.328275	1.00147	0.0111324	0.89482	0.00353884	0.00315024	0.00877054	-0.000837093	-0.00179206	0.640419	-0.0069099	0.00232405	0.00294739	0.00566985	0.00354658	0.109983	0.001375	0.005007	0.737971	NA	0.00587261	1.18E-49	
21811154	9	rs10811623	9:21811154 G	A	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
21813241	9	rs107269156	9:21813241 C	T	1.01242	0.00679989	0.0693861	1.00736	0.0112005	0.51293	-0.0044545	0.00135818	0.00103905	0.000119742	0.00180279	0.947043	0.00702029	0.0033831	0.00267767	-0.0075661	0.00356829	0.033975	-0.001464	0.005046	0.717767	NA	0.00593932	3.76E-38	
21813303	9	rs107269156	9:21813303 T	C	1.01242	0.00679971	0.0693802	1.0074	0.012005	0.51047	-0.0044592	0.00135815	0.00102627	0.000122807	0.00180276	0.945689	0.00700731	0.0033808	0.00272632	-0.007559	0.00356822	0.034196	-0.001495	0.005046	0.766595	NA	0.00593957	3.78E-38	
21813495	9	rs107269156	9:21813495 T	C	1.01233	0.00680293	0.0717386	1.00723	0.012063	0.520118	-0.0044377	0.00135886	0.00137668	6.95E-05	0.00180376	0.969266	0.00710077	0.0033939	0.00240312	-0.007432	0.00357011	0.0373677	-0.001542	0.005046	0.759926	3.19E-38	0.00594133	3.19E-38	
21813518	9	rs107269156	9:21813518 T	C	1.01231	0.00680017	0.0718818	1.00743	0.012013	0.508444	-0.0044454	0.00135887	0.00095917	0.000135397	0.00180292	0.943136	0.00702335	0.0033829	0.0026795	-0.0075971	0.00356854	0.033262	-0.001412	0.005046	0.779574	3.58E-38	0.00593765	3.58E-38	
21816528	9	rs10723329	9:21816528 G	A	0.992353	0.00673554	0.254839	0.99341	0.011099	0.551358	0.002																		

Supplementary Table 3. MPRA results for selected variants in the MTAP/CDKN2A and CASP8 regions. 'Function' refers to the inferred function of a SNP, activator means that the alternative allele is significantly associated to higher mRNA expression of the target gene. 'UACC903/HEK293' refers to analyses considering both cells together, 'UACC903 Only' refers to these cells considered alone. FDR: False discovery rate.

<i>CDKN2A</i>								
			UACC903/HEK293			UACC903 Only		
MPRA rsID	ref	alt	function	log2 alt/ref	FDR alt/ref	function	log2 alt/ref	FDR alt/ref
rs10811617	A	C	activator	-0.1115834	0.0003498	NA	-0.1310841	0.04907075
rs10811618	G	C	NA	-0.0069935	0.49136839	NA	-0.02485	0.82045209
rs4364717	A	G	NA	0.03813089	0.46598857	NA	0.0041674	0.97400112
rs935055	G	C	NA	-0.1888638	0.01917813	NA	-0.5283158	0.06744791
rs871024	C	A	NA	0.0282317	0.21580096	NA	0.11130019	0.24016397
rs869330	A	G	NA	-0.098019	0.12720868	NA	-0.2419938	0.26797427
rs869329	A	G	NA	0.04421337	0.1503776	NA	0.09470067	0.38789033
rs80138396	C	CAG	NA	0.13444829	0.000078444	NA	0.21305865	0.01296601
rs10811623	A	G	NA	-0.0130452	0.49494295	NA	-0.0456452	0.52647324
rs72691562	A	C	NA	-0.0123984	0.88597614	NA	0.01065259	0.97400112
rs72691563	C	T	NA	0.00878286	0.30528242	NA	0.09554636	0.24649207
rs72691564	C	T	NA	-0.0581653	0.07100476	NA	-0.1410606	0.16889296
rs34710113	GT	G	NA	-0.030248698	0.697851764	NA	-0.073210005	0.714809983
<i>CASP8</i>								
			903/HEK			903 Only		
MPRA rsID	ref	alt	function	log2 alt/ref	FDR alt/ref	function	log2 alt/ref	FDR alt/ref
rs3769823	A	G	activator	-0.364734794	3.06543E-18	activator	-0.648012254	1.85585E-12
rs1861270	A	G	NA	-0.091384646	0.40396426	NA	-0.332661928	0.539449943
rs2349070	A	C	NA	0.174687342	0.156229406	NA	0.208464406	0.984241149
rs6737085	T	A	NA	-0.044147357	0.507201012	NA	0.090314509	0.556421584
rs2540334	C	T	NA	0.129891041	0.062687748	NA	0.037778019	0.736362581

Supplementary Table 5. Transcription start sites annotated for each gene of interest. Coordinates are in GRCh37.

Gene stable ID	strand	chr	transcript_name	transcript_stable_id	start_coord
ENSG00000049656	-1	5	CLPTM1L-008	ENST00000507807	1341853
ENSG00000049656	-1	5	CLPTM1L-007	ENST00000507195	1326551
ENSG00000049656	-1	5	CLPTM1L-010	ENST00000506641	1326370
ENSG00000003402	1	2	CFLAR-015	ENST00000441224	201981560
ENSG00000003402	1	2	CFLAR-016	ENST00000433445	201981762
ENSG00000003402	1	2	CFLAR-008	ENST00000423241	201983214
ENSG00000003402	1	2	CFLAR-009	ENST00000439154	201983387
ENSG00000003402	1	2	CFLAR-027	ENST00000490965	201983246
ENSG00000003402	1	2	CFLAR-017	ENST00000425030	201987200
ENSG00000003402	1	2	CFLAR-010	ENST00000440180	201994226
ENSG00000003402	1	2	CFLAR-018	ENST00000417748	201994052
ENSG00000003402	1	2	CFLAR-021	ENST00000494258	201997502
ENSG00000003402	1	2	CFLAR-022	ENST00000470178	201997595
ENSG00000003402	1	2	CFLAR-023	ENST00000462763	201997676
ENSG00000172927	1	11	MYEOV-009	ENST00000544781	69066741
ENSG00000101440	1	20	ASIP-002	ENST00000568305	32782375
ENSG00000183844	1	21	FAM3B-005	ENST00000398646	42694747
ENSG00000183844	1	21	FAM3B-001	ENST00000357985	42688661
ENSG00000183844	1	21	FAM3B-002	ENST00000479810	42676139
ENSG00000183844	1	21	FAM3B-006	ENST00000518236	42676177
ENSG00000099810	1	9	MTAP-013	ENST00000427788	21803277
ENSG00000147889	-1	9	CDKN2A-007	ENST00000470819	21994872
ENSG00000147889	-1	9	CDKN2A-001	ENST00000304494	21975097
ENSG00000147889	-1	9	CDKN2A-003	ENST00000380151	21974826
ENSG00000147889	-1	9	CDKN2A-009	ENST00000498124	21974865
ENSG00000147889	-1	9	CDKN2A-014	ENST00000579122	21974857
ENSG00000149311	1	11	ATM-003	ENST00000452508	108093843
ENSG00000149311	1	11	ATM-016	ENST00000532931	108093817
ENSG00000149311	1	11	ATM-026	ENST00000527891	108093812
ENSG00000149311	1	11	ATM-004	ENST00000526567	108094256
ENSG00000100151	1	22	PICK1-002	ENST00000356976	38453414
ENSG00000100151	1	22	PICK1-006	ENST00000476157	38453411
ENSG00000100151	1	22	PICK1-007	ENST00000468288	38453411
ENSG00000100151	1	22	PICK1-011	ENST00000469819	38453414
ENSG00000100151	1	22	PICK1-013	ENST00000426258	38453411
ENSG00000100151	1	22	PICK1-016	ENST00000437453	38453402
ENSG00000064012	1	2	CASP8-001	ENST00000437283	202122841
ENSG00000064012	1	2	CASP8-002	ENST00000358485	202122759
ENSG00000064012	1	2	CASP8-007	ENST00000339403	202123047
ENSG00000064012	1	2	CASP8-010	ENST00000447616	202122703
ENSG00000064012	1	2	CASP8-011	ENST00000490412	202122842
ENSG00000064012	1	2	CASP8-023	ENST00000413726	202122841
ENSG00000064012	1	2	CASP8-012	ENST00000323492	202125223
ENSG00000064012	1	2	CASP8-026	ENST00000429881	202126679
ENSG00000140718	1	16	FTO-002	ENST00000460382	53920842
ENSG00000140718	1	16	FTO-006	ENST00000431610	53920829
ENSG00000140718	1	16	FTO-007	ENST00000472835	54097549
ENSG00000183486	1	21	MX2-008	ENST00000418103	42742441
ENSG00000183486	1	21	MX2-009	ENST00000416447	42742140
ENSG00000143379	1	1	SETDB1-008	ENST00000423081	150899116
ENSG00000184381	-1	22	PLA2G6-005	ENST00000417303	38588107
ENSG00000184381	-1	22	PLA2G6-008	ENST00000452972	38564097
ENSG00000184381	-1	22	PLA2G6-009	ENST00000479641	38564084
ENSG00000184381	-1	22	PLA2G6-015	ENST00000498338	38539501
ENSG00000086991	-1	11	NOX4-006	ENST00000528341	89223900
ENSG00000086991	-1	11	NOX4-005	ENST00000343727	89224299

IV6-1887752-1887764	IV6-1887752-1887764	1	700	CantonRegion	500	1	0
IV6-1887765-1887777	IV6-1887765-1887777	1	200	CantonRegion	500	1	0
IV6-1887778-1887790	IV6-1887778-1887790	1	400	CantonRegion	500	1	0
IV6-1887801-1887813	IV6-1887801-1887813	1	400	CantonRegion	500	1	0
IV6-1887814-1887826	IV6-1887814-1887826	1	400	CantonRegion	500	1	0
IV6-1887827-1887839	IV6-1887827-1887839	1	400	CantonRegion	500	1	0
IV6-1887840-1887852	IV6-1887840-1887852	1	400	CantonRegion	500	1	0
IV6-1887853-1887865	IV6-1887853-1887865	1	400	CantonRegion	500	1	0
IV6-1887866-1887878	IV6-1887866-1887878	1	400	CantonRegion	500	1	0
IV6-1887879-1887891	IV6-1887879-1887891	1	400	CantonRegion	500	1	0
IV6-1887892-1887904	IV6-1887892-1887904	1	400	CantonRegion	500	1	0
IV6-1887905-1887917	IV6-1887905-1887917	1	400	CantonRegion	500	1	0
IV6-1887918-1887930	IV6-1887918-1887930	1	400	CantonRegion	500	1	0
IV6-1887931-1887943	IV6-1887931-1887943	1	400	CantonRegion	500	1	0
IV6-1887944-1887956	IV6-1887944-1887956	1	400	CantonRegion	500	1	0
IV6-1887957-1887969	IV6-1887957-1887969	1	400	CantonRegion	500	1	0
IV6-1887970-1887982	IV6-1887970-1887982	1	400	CantonRegion	500	1	0
IV6-1887983-1887995	IV6-1887983-1887995	1	400	CantonRegion	500	1	0
IV6-1887996-1888008	IV6-1887996-1888008	1	400	CantonRegion	500	1	0
IV6-1888009-1888021	IV6-1888009-1888021	1	400	CantonRegion	500	1	0
IV6-1888022-1888034	IV6-1888022-1888034	1	400	CantonRegion	500	1	0
IV6-1888035-1888047	IV6-1888035-1888047	1	400	CantonRegion	500	1	0
IV6-1888048-1888060	IV6-1888048-1888060	1	400	CantonRegion	500	1	0
IV6-1888061-1888073	IV6-1888061-1888073	1	400	CantonRegion	500	1	0
IV6-1888074-1888086	IV6-1888074-1888086	1	400	CantonRegion	500	1	0
IV6-1888087-1888100	IV6-1888087-1888100	1	400	CantonRegion	500	1	0
IV6-1888101-1888113	IV6-1888101-1888113	1	400	CantonRegion	500	1	0
IV6-1888114-1888126	IV6-1888114-1888126	1	400	CantonRegion	500	1	0
IV6-1888127-1888139	IV6-1888127-1888139	1	400	CantonRegion	500	1	0
IV6-1888140-1888152	IV6-1888140-1888152	1	400	CantonRegion	500	1	0
IV6-1888153-1888165	IV6-1888153-1888165	1	400	CantonRegion	500	1	0
IV6-1888166-1888178	IV6-1888166-1888178	1	400	CantonRegion	500	1	0
IV6-1888179-1888191	IV6-1888179-1888191	1	400	CantonRegion	500	1	0
IV6-1888192-1888204	IV6-1888192-1888204	1	400	CantonRegion	500	1	0
IV6-1888205-1888217	IV6-1888205-1888217	1	400	CantonRegion	500	1	0
IV6-1888218-1888230	IV6-1888218-1888230	1	400	CantonRegion	500	1	0
IV6-1888231-1888243	IV6-1888231-1888243	1	400	CantonRegion	500	1	0
IV6-1888244-1888256	IV6-1888244-1888256	1	400	CantonRegion	500	1	0
IV6-1888257-1888269	IV6-1888257-1888269	1	400	CantonRegion	500	1	0
IV6-1888270-1888282	IV6-1888270-1888282	1	400	CantonRegion	500	1	0
IV6-1888283-1888295	IV6-1888283-1888295	1	400	CantonRegion	500	1	0
IV6-1888296-1888308	IV6-1888296-1888308	1	400	CantonRegion	500	1	0
IV6-1888309-1888321	IV6-1888309-1888321	1	400	CantonRegion	500	1	0
IV6-1888322-1888334	IV6-1888322-1888334	1	400	CantonRegion	500	1	0
IV6-1888335-1888347	IV6-1888335-1888347	1	400	CantonRegion	500	1	0
IV6-1888348-1888360	IV6-1888348-1888360	1	400	CantonRegion	500	1	0
IV6-1888361-1888373	IV6-1888361-1888373	1	400	CantonRegion	500	1	0
IV6-1888374-1888386	IV6-1888374-1888386	1	400	CantonRegion	500	1	0
IV6-1888387-1888399	IV6-1888387-1888399	1	400	CantonRegion	500	1	0
IV6-1888400-1888412	IV6-1888400-1888412	1	400	CantonRegion	500	1	0
IV6-1888413-1888425	IV6-1888413-1888425	1	400	CantonRegion	500	1	0
IV6-1888426-1888438	IV6-1888426-1888438	1	400	CantonRegion	500	1	0
IV6-1888439-1888451	IV6-1888439-1888451	1	400	CantonRegion	500	1	0
IV6-1888452-1888464	IV6-1888452-1888464	1	400	CantonRegion	500	1	0
IV6-1888465-1888477	IV6-1888465-1888477	1	400	CantonRegion	500	1	0
IV6-1888478-1888490	IV6-1888478-1888490	1	400	CantonRegion	500	1	0
IV6-1888491-1888503	IV6-1888491-1888503	1	400	CantonRegion	500	1	0
IV6-1888504-1888516	IV6-1888504-1888516	1	400	CantonRegion	500	1	0
IV6-1888517-1888529	IV6-1888517-1888529	1	400	CantonRegion	500	1	0
IV6-1888530-1888542	IV6-1888530-1888542	1	400	CantonRegion	500	1	0
IV6-1888543-1888555	IV6-1888543-1888555	1	400	CantonRegion	500	1	0
IV6-1888556-1888568	IV6-1888556-1888568	1	400	CantonRegion	500	1	0
IV6-1888569-1888581	IV6-1888569-1888581	1	400	CantonRegion	500	1	0
IV6-1888582-1888594	IV6-1888582-1888594	1	400	CantonRegion	500	1	0
IV6-1888595-1888607	IV6-1888595-1888607	1	400	CantonRegion	500	1	0
IV6-1888608-1888620	IV6-1888608-1888620	1	400	CantonRegion	500	1	0
IV6-1888621-1888633	IV6-1888621-1888633	1	400	CantonRegion	500	1	0
IV6-1888634-1888646	IV6-1888634-1888646	1	400	CantonRegion	500	1	0
IV6-1888647-1888659	IV6-1888647-1888659	1	400	CantonRegion	500	1	0
IV6-1888660-1888672	IV6-1888660-1888672	1	400	CantonRegion	500	1	0
IV6-1888673-1888685	IV6-1888673-1888685	1	400	CantonRegion	500	1	0
IV6-1888686-1888698	IV6-1888686-1888698	1	400	CantonRegion	500	1	0
IV6-1888699-1888711	IV6-1888699-1888711	1	400	CantonRegion	500	1	0
IV6-1888712-1888724	IV6-1888712-1888724	1	400	CantonRegion	500	1	0
IV6-1888725-1888737	IV6-1888725-1888737	1	400	CantonRegion	500	1	0
IV6-1888738-1888750	IV6-1888738-1888750	1	400	CantonRegion	500	1	0
IV6-1888751-1888763	IV6-1888751-1888763	1	400	CantonRegion	500	1	0
IV6-1888764-1888776	IV6-1888764-1888776	1	400	CantonRegion	500	1	0
IV6-1888777-1888789	IV6-1888777-1888789	1	400	CantonRegion	500	1	0
IV6-1888790-1888802	IV6-1888790-1888802	1	400	CantonRegion	500	1	0
IV6-1888803-1888815	IV6-1888803-1888815	1	400	CantonRegion	500	1	0
IV6-1888816-1888828	IV6-1888816-1888828	1	400	CantonRegion	500	1	0
IV6-1888829-1888841	IV6-1888829-1888841	1	400	CantonRegion	500	1	0
IV6-1888842-1888854	IV6-1888842-1888854	1	400	CantonRegion	500	1	0
IV6-1888855-1888867	IV6-1888855-1888867	1	400	CantonRegion	500	1	0
IV6-1888868-1888880	IV6-1888868-1888880	1	400	CantonRegion	500	1	0
IV6-1888881-1888893	IV6-1888881-1888893	1	400	CantonRegion	500	1	0
IV6-1888894-1888906	IV6-1888894-1888906	1	400	CantonRegion	500	1	0
IV6-1888907-1888919	IV6-1888907-1888919	1	400	CantonRegion	500	1	0
IV6-1888920-1888932	IV6-1888920-1888932	1	400	CantonRegion	500	1	0
IV6-1888933-1888945	IV6-1888933-1888945	1	400	CantonRegion	500	1	0
IV6-1888946-1888958	IV6-1888946-1888958	1	400	CantonRegion	500	1	0
IV6-1888959-1888971	IV6-1888959-1888971	1	400	CantonRegion	500	1	0
IV6-1888972-1888984	IV6-1888972-1888984	1	400	CantonRegion	500	1	0
IV6-1888985-1888997	IV6-1888985-1888997	1	400	CantonRegion	500	1	0
IV6-1889000-1889012	IV6-1889000-1889012	1	400	CantonRegion	500	1	0
IV6-1889013-1889025	IV6-1889013-1889025	1	400	CantonRegion	500	1	0
IV6-1889026-1889038	IV6-1889026-1889038	1	400	CantonRegion	500	1	0
IV6-1889039-1889051	IV6-1889039-1889051	1	400	CantonRegion	500	1	0
IV6-1889052-1889064	IV6-1889052-1889064	1	400	CantonRegion	500	1	0
IV6-1889065-1889077	IV6-1889065-1889077	1	400	CantonRegion	500	1	0
IV6-1889078-1889090	IV6-1889078-1889090	1	400	CantonRegion	500	1	0
IV6-1889093-1889105	IV6-1889093-1889105	1	400	CantonRegion	500	1	0
IV6-1889106-1889118	IV6-1889106-1889118	1	400	CantonRegion	500	1	0
IV6-1889119-1889131	IV6-1889119-1889131	1	400	CantonRegion	500	1	0
IV6-1889132-1889144	IV6-1889132-1889144	1	400	CantonRegion	500	1	0
IV6-1889145-1889157	IV6-1889145-1889157	1	400	CantonRegion	500	1	0
IV6-1889158-1889170	IV6-1889158-1889170	1	400	CantonRegion	500	1	0
IV6-1889171-1889183	IV6-1889171-1889183	1	400	CantonRegion	500	1	0
IV6-1889184-1889196	IV6-1889184-1889196	1	400	CantonRegion	500	1	0
IV6-1889197-1889209	IV6-1889197-1889209	1	400	CantonRegion	500	1	0
IV6-1889210-1889222	IV6-1889210-1889222	1	400	CantonRegion	500	1	0
IV6-1889223-1889235	IV6-1889223-1889235	1	400	CantonRegion	500	1	0
IV6-1889236-1889248	IV6-1889236-1889248	1	400	CantonRegion	500	1	0
IV6-1889249-1889261	IV6-1889249-1889261	1	400	CantonRegion	500	1	0
IV6-1889262-1889274	IV6-1889262-1889274	1	400	CantonRegion	500	1	0
IV6-1889275-1889287	IV6-1889275-1889287	1	400	CantonRegion	500	1	0
IV6-1889288-1889300	IV6-1889288-1889300	1	400	CantonRegion	500	1	0
IV6-1889301-1889313	IV6-1889301-1889313	1	400	CantonRegion	500	1	0
IV6-1889314-1889326	IV6-1889314-1889326	1	400	CantonRegion	500	1	0
IV6-1889327-1889339	IV6-1889327-1889339	1	400	CantonRegion	500	1	0
IV6-1889340-1889352	IV6-1889340-1889352	1	400	CantonRegion	500	1	0
IV6-1889353-1889365	IV6-1889353-1889365	1	400	CantonRegion	500	1	0
IV6-1889366-1889378	IV6-1889366-1889378	1	400	CantonRegion	500	1	0
IV6-1889379-1889391	IV6-1889379-1889391	1	400	CantonRegion	500	1	0
IV6-1889392-1889404	IV6-1889392-1889404	1	400	CantonRegion	500	1	0
IV6-1889405-1889417	IV6-1889405-1889417	1	400	CantonRegion	500	1	0
IV6-1889418-1889430	IV6-1889418-1889430	1	400	CantonRegion	500	1	0
IV6-1889431-1889443	IV6-1889431-1889443	1	400	CantonRegion	500	1	0
IV6-1889444-1889456	IV6-1889444-1889456	1	400	CantonRegion	500	1	0
IV6-1889457-1889469	IV6-1889457-1889469	1	400	CantonRegion	500	1	0
IV6-1889470-1889482	IV6-1889470-1889482	1	400	CantonRegion	500	1	0
IV6-1889483-1889495	IV6-1889483-1889495	1	400	CantonRegion	500	1	0
IV6-1889496-1889508	IV6-1889496-1889508	1					

015248873	015248873-015248873	1	2567	CastorRegion	500	1	0
015248874	015248874-015248874	1	108	CastorRegion	500	1	0
015248875	015248875-015248875	1	400	CastorRegion	500	1	0
015248876	015248876-015248876	1	100	CastorRegion	500	1	0
015248877	015248877-015248877	1	400	CastorRegion	500	1	0
015248878	015248878-015248878	1	206	CastorRegion	500	1	0
015248879	015248879-015248879	1	176	CastorRegion	500	1	0
015248880	015248880-015248880	1	279	CastorRegion	500	1	0
015248881	015248881-015248881	1	520	CastorRegion	500	1	0
015248882	015248882-015248882	1	206	CastorRegion	500	1	0
015248883	015248883-015248883	1	303	CastorRegion	500	1	0
015248884	015248884-015248884	1	276	CastorRegion	500	1	0
015248885	015248885-015248885	1	216	CastorRegion	500	1	0
015248886	015248886-015248886	1	400	CastorRegion	500	1	0
015248887	015248887-015248887	1	400	CastorRegion	500	1	0
015248888	015248888-015248888	1	237	CastorRegion	500	1	0
015248889	015248889-015248889	1	400	CastorRegion	500	1	0
015248890	015248890-015248890	1	400	CastorRegion	500	1	0
015248891	015248891-015248891	1	400	CastorRegion	500	1	0
015248892	015248892-015248892	1	400	CastorRegion	500	1	0
015248893	015248893-015248893	1	400	CastorRegion	500	1	0
015248894	015248894-015248894	1	400	CastorRegion	500	1	0
015248895	015248895-015248895	1	400	CastorRegion	500	1	0
015248896	015248896-015248896	1	400	CastorRegion	500	1	0
015248897	015248897-015248897	1	400	CastorRegion	500	1	0
015248898	015248898-015248898	1	400	CastorRegion	500	1	0
015248899	015248899-015248899	1	400	CastorRegion	500	1	0
015248900	015248900-015248900	1	400	CastorRegion	500	1	0
015248901	015248901-015248901	1	400	CastorRegion	500	1	0
015248902	015248902-015248902	1	400	CastorRegion	500	1	0
015248903	015248903-015248903	1	400	CastorRegion	500	1	0
015248904	015248904-015248904	1	400	CastorRegion	500	1	0
015248905	015248905-015248905	1	400	CastorRegion	500	1	0
015248906	015248906-015248906	1	400	CastorRegion	500	1	0
015248907	015248907-015248907	1	400	CastorRegion	500	1	0
015248908	015248908-015248908	1	400	CastorRegion	500	1	0
015248909	015248909-015248909	1	400	CastorRegion	500	1	0
015248910	015248910-015248910	1	400	CastorRegion	500	1	0
015248911	015248911-015248911	1	400	CastorRegion	500	1	0
015248912	015248912-015248912	1	400	CastorRegion	500	1	0
015248913	015248913-015248913	1	400	CastorRegion	500	1	0
015248914	015248914-015248914	1	400	CastorRegion	500	1	0
015248915	015248915-015248915	1	400	CastorRegion	500	1	0
015248916	015248916-015248916	1	400	CastorRegion	500	1	0
015248917	015248917-015248917	1	400	CastorRegion	500	1	0
015248918	015248918-015248918	1	400	CastorRegion	500	1	0
015248919	015248919-015248919	1	400	CastorRegion	500	1	0
015248920	015248920-015248920	1	400	CastorRegion	500	1	0
015248921	015248921-015248921	1	400	CastorRegion	500	1	0
015248922	015248922-015248922	1	400	CastorRegion	500	1	0
015248923	015248923-015248923	1	400	CastorRegion	500	1	0
015248924	015248924-015248924	1	400	CastorRegion	500	1	0
015248925	015248925-015248925	1	400	CastorRegion	500	1	0
015248926	015248926-015248926	1	400	CastorRegion	500	1	0
015248927	015248927-015248927	1	400	CastorRegion	500	1	0
015248928	015248928-015248928	1	400	CastorRegion	500	1	0
015248929	015248929-015248929	1	400	CastorRegion	500	1	0
015248930	015248930-015248930	1	400	CastorRegion	500	1	0
015248931	015248931-015248931	1	400	CastorRegion	500	1	0
015248932	015248932-015248932	1	400	CastorRegion	500	1	0
015248933	015248933-015248933	1	400	CastorRegion	500	1	0
015248934	015248934-015248934	1	400	CastorRegion	500	1	0
015248935	015248935-015248935	1	400	CastorRegion	500	1	0
015248936	015248936-015248936	1	400	CastorRegion	500	1	0
015248937	015248937-015248937	1	400	CastorRegion	500	1	0
015248938	015248938-015248938	1	400	CastorRegion	500	1	0
015248939	015248939-015248939	1	400	CastorRegion	500	1	0
015248940	015248940-015248940	1	400	CastorRegion	500	1	0
015248941	015248941-015248941	1	400	CastorRegion	500	1	0
015248942	015248942-015248942	1	400	CastorRegion	500	1	0
015248943	015248943-015248943	1	400	CastorRegion	500	1	0
015248944	015248944-015248944	1	400	CastorRegion	500	1	0
015248945	015248945-015248945	1	400	CastorRegion	500	1	0
015248946	015248946-015248946	1	400	CastorRegion	500	1	0
015248947	015248947-015248947	1	400	CastorRegion	500	1	0
015248948	015248948-015248948	1	400	CastorRegion	500	1	0
015248949	015248949-015248949	1	400	CastorRegion	500	1	0
015248950	015248950-015248950	1	400	CastorRegion	500	1	0
015248951	015248951-015248951	1	400	CastorRegion	500	1	0
015248952	015248952-015248952	1	400	CastorRegion	500	1	0
015248953	015248953-015248953	1	400	CastorRegion	500	1	0
015248954	015248954-015248954	1	400	CastorRegion	500	1	0
015248955	015248955-015248955	1	400	CastorRegion	500	1	0
015248956	015248956-015248956	1	400	CastorRegion	500	1	0
015248957	015248957-015248957	1	400	CastorRegion	500	1	0
015248958	015248958-015248958	1	400	CastorRegion	500	1	0
015248959	015248959-015248959	1	400	CastorRegion	500	1	0
015248960	015248960-015248960	1	400	CastorRegion	500	1	0
015248961	015248961-015248961	1	400	CastorRegion	500	1	0
015248962	015248962-015248962	1	400	CastorRegion	500	1	0
015248963	015248963-015248963	1	400	CastorRegion	500	1	0
015248964	015248964-015248964	1	400	CastorRegion	500	1	0
015248965	015248965-015248965	1	400	CastorRegion	500	1	0
015248966	015248966-015248966	1	400	CastorRegion	500	1	0
015248967	015248967-015248967	1	400	CastorRegion	500	1	0
015248968	015248968-015248968	1	400	CastorRegion	500	1	0
015248969	015248969-015248969	1	400	CastorRegion	500	1	0
015248970	015248970-015248970	1	400	CastorRegion	500	1	0
015248971	015248971-015248971	1	400	CastorRegion	500	1	0
015248972	015248972-015248972	1	400	CastorRegion	500	1	0
015248973	015248973-015248973	1	400	CastorRegion	500	1	0
015248974	015248974-015248974	1	400	CastorRegion	500	1	0
015248975	015248975-015248975	1	400	CastorRegion	500	1	0
015248976	015248976-015248976	1	400	CastorRegion	500	1	0
015248977	015248977-015248977	1	400	CastorRegion	500	1	0
015248978	015248978-015248978	1	400	CastorRegion	500	1	0
015248979	015248979-015248979	1	400	CastorRegion	500	1	0
015248980	015248980-015248980	1	400	CastorRegion	500	1	0
015248981	015248981-015248981	1	400	CastorRegion	500	1	0
015248982	015248982-015248982	1	400	CastorRegion	500	1	0
015248983	015248983-015248983	1	400	CastorRegion	500	1	0
015248984	015248984-015248984	1	400	CastorRegion	500	1	0
015248985	015248985-015248985	1	400	CastorRegion	500	1	0
015248986	015248986-015248986	1	400	CastorRegion	500	1	0
015248987	015248987-015248987	1	400	CastorRegion	500	1	0
015248988	015248988-015248988	1	400	CastorRegion	500	1	0
015248989	015248989-015248989	1	400	CastorRegion	500	1	0
015248990	015248990-015248990	1	400	CastorRegion	500	1	0
015248991	015248991-015248991	1	400	CastorRegion	500	1	0
015248992	015248992-015248992	1	400	CastorRegion	500	1	0
015248993	015248993-015248993	1	400	CastorRegion	500	1	0
015248994	015248994-015248994	1	400	CastorRegion	500	1	0
015248995	015248995-015248995	1	400	CastorRegion	500	1	0
015248996	015248996-015248996	1	400	CastorRegion	500	1	0
015248997	015248997-015248997	1	400	CastorRegion	500	1	0
015248998	015248998-015248998	1	400	CastorRegion	500	1	0
015248999	015248999-015248999	1	400	CastorRegion	500	1	0
015249000	015249000-015249000	1	400	CastorRegion	500	1	0

